Risk factors for recurrent thrombosis and comparison of DOACs vs VKA in selected thrombotic antiphospholipid syndrome

Risk factors for recurrent thrombosis and comparison of DOACs vs VKA in selected thrombotic antiphospholipid syndrome | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Risk factors for recurrent thrombosis and comparison of DOACs vs VKA in selected thrombotic antiphospholipid syndrome LEMESLE Guillaume, BOUZILLE Guillaume, BELHOMME Nicolas, ROUSSEAU Chloé, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3951851/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Introduction : Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of autoantibodies (anti-cardiolipin, anti-β2GP1, and lupus anticoagulant) associated with arterial, venous, or microcirculatory thrombotic events and/or obstetrical events (miscarriages, fetal death, and preterm deliveries). The treatment of thrombotic events is based on long-term anticoagulant therapy with vitamin K antagonist (VKA). Direct oral anticoagulants (DOACs) are not recommended by international guidelines as first-line therapy because of an increased risk of recurrent thrombosis observed in several randomized trials. This study aimed to report a cohort of patients with thrombotic antiphospholipid syndrome (TAPS) to identify risk factors associated with recurrent thrombosis and to identify differences between patients treated with VKA and patients treated with DOACs. Materials and methods : We collected data from 207 patients with TAPS from an initial population of 655 patients identified by automated screening software. Results : This retrospective longitudinal analysis based on real-life data confirmed previously identified risk factors for thrombotic recurrence, such as the absence of antithrombotic treatment following the initial thrombotic event, treatment with antiplatelet treatment alone following the initial thrombotic event. No difference between patients treated with VKA (n=123) or DOACs (n=50) were observed on the risk of recurrent thrombosis. Patients with VKA versus DOACs had more frequently triple APL positivity, presence of lupus anticoagulant and absence of an initial venous thrombotic event. Conclusions : This results suggest a potential use of DOACs in the treatment of TAPS for patients with a primary VTE event and a single APL positivity profile, although its retrospective design prevents firm recommendations. Internal Medicine thrombosis antiphospholipid syndrome vitamin K antagonist direct oral anticoagulants Figures Figure 1 Figure 2 Figure 3 1. Introduction Antiphospholipid syndrome (APS) is an auto-immune disease characterized by venous, arterial or microvascular thrombosis and/or pregnancy morbidity associated to persistence of antiphospholipid antibodies (APL), namely lupus anticoagulant (LA), IgG and IgM anticardiolipin (aCL), and IgG and IgM anti-β2-glycoprotein-I antibodies (aβ2GPI) 1 . The pathophysiology of thrombotic antiphospholipid syndrome (TAPS) is thought to involve the generation APL which create a prothrombotic state through different pathways; including a) binding to endothelial cells b) increasing tissue factor secretion, c) triggering platelet aggregation, d) increasing neutrophil extracellular traps (NET) formation, diminishing their clearance and inducing complement activation 2 . APS is considered primary APS when isolated or secondary APS when associated with other auto-immune diseases especially systemic lupus erythematosus (SLE). Obstetrical antiphospholipid syndrome (OAPS) is defined by obstetric event in the absence of any thrombotic manifestations. Patients with TAPS are at high risk for recurrent thrombosis and are usually treated with long-term oral anticoagulation using vitamin K antagonist (VKA) in regards of recent guidelines 3 . Risk stratification studies highlight risks of recurrent thrombosis according to clinical and biological APS phenotypes 4 . Thus, patients with arterial thrombosis, patients with double or triple APL positivity as well as patients with persistent LA are considered at high risk of recurrent thrombosis and should be treated with VKA in regards of recent randomized controlled trials (RCT) 5–7 with or without antiplatelet therapy (APT) depending of the underlying comorbidities. Although VKA are the standard of care for patients with TAPS, their daily use is complex due to a narrow therapeutic range requiring regular monitoring of the international normalized ratio (INR) and interactions with drugs and diet. Thus, in clinical practice, patients are often treated with direct oral anticoagulants (DOACs) because of difficulties to obtain a stable INR, bleeding or VKA intolerance. In addition, in case of a first venous thrombotic event and non-high risk APL profile, it is still unclear whether DOACs are an option for anticoagulation 8,9 . There is still need for a better characterization of TAPS patient profiles to identify those who could benefit from DOACs in this indication 10,11 . In this study, we aimed to report a cohort of patients with TAPS in order to identify risk factors associated with recurrent thrombosis. We also aimed to identify differences between patients treated with VKA and patients treated with DOACs based on real life data. 2. Methods 2.1 Patients We conducted a retrospective longitudinal monocentric study in a French referral center. Using a Ehop screening software 12 , we identified patients with persistent positive APL using the following keywords : antiphospholipid syndrome, lupus anticoagulant, anticardiolipin antibodies, anti-β2-glycoprotein-I antibodies. All patients fulfilling the international Sydney criteria 1 for TAPS were included : at least one thrombotic event (involving artery of any caliber, deep vein or microvascular vessels) and persistence of significantly high APL titles at least 12 weeks apart (positive result of LA and/or aCL IgG or IgM and/or aβ2GPI IgG or IgM > 99th percentile as per our reference laboratory). Patients were included at TAPS diagnosis defined as the time of the confirmation of persistent APL biology. Long-term antithrombotic treatment was defined as the treatment initiated and/or maintained after diagnosis confirmation. The following characteristics were collected at APS diagnosis (ie, time of the second APL positivity) : Age, gender Venous morbidity defined as any history of previous venous thromboembolism (VTE) event, deep or superficial Arterial morbidity defined as any history of atrial fibrillation, peripheral artery disease, arterial embolism, myocardial infarction or ischemic stroke Cardiovascular risk factors (smoking, diabetes mellitus, arterial hypertension, dyslipidemia, obesity defined as BMI > 30kg/m², oral contraceptive use) Systemic auto-immune diseases associated defined as presence of SLE, Sjögren syndrome, rheumatoid arthritis, spondyloarthritis or thyroiditis Ongoing and previous treatment with APT, VKA, DOACs, statins, hydroxychloroquine and corticosteroids Previously known OAPS Characteristics of the primary thrombotic event defined as the thrombotic event leading to TAPS diagnosis. Unusual thrombotic venous localization such as splanchnic vein thrombosis, adrenal vein thrombosis, renal vein thrombosis, cerebral venous thrombosis, pelvic vein thrombosis, upper limb thrombosis were referred as “other”. Unusual thrombotic arterial localization such as splanchnic arterial thrombosis, adrenal arterial thrombosis, arterial limb thrombosis, renal arterial thrombosis and pelvic arterial thrombosis were referred as “other”. APL profile. Single APL positivity was defined as one persistent positivity of LA or aCL or aβ2GPI, double APL positivity as two persistent positivity of LA, aCL or aβ2GPI, and triple APL positivity as persistent positivity of LA, aCL and aβ2GPI. During follow-up, we also collected the following events: recurrent thrombosis, bleedings and subsequent antithrombotic treatment modifications. Recurrent thrombosis were defined as new vascular occlusion concerning deep vein, artery of any caliber or microvascular vessels confirmed by imaging or histology. Bleedings were reported as major and non-major according to the International Society on Thrombosis and Haemostasis (ISTH) guidelines 13 . Major bleedings were defined as fatal, involving a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, or intramuscular with compartment syndrome, causing a fall in hemoglobin level of 20g/L or more or leading to transfusion of two or more unit of whole blood or red cells. Non-major bleedings were defined as any sign or symptom of hemorrhage requiring medical intervention by a healthcare professional, leading to hospitalization or prompting a face to face evaluation 13 . The study was approved by a local ethics committee (approval 21.58). All patients were informed by mail of the use of their data and had a 3 weeks deadline after reception to express their opposition to the study. 2.2 Statistical analysis Continuous variables were reported as medians (interquartile range (IQR)) or means (standard deviation (SD)) and dichotomous variables by frequency distribution and percentage. Risk factors for recurrent thrombosis and bleedings were identified using a Cox model with competitive risk. Variables with a p-value < 0,2 were included in a multivariate analysis which was followed by a backward stepwise elimination. Colinear variables were not included together in a same model. A two tailed p-value < 0,05 was considered statistically significant. Cumulative incidence curves were also presented using a Cox model. Categorial variables associated with DOACs, VKA, APT alone and no treatment, were identified using logistic regression. Variables with a p-value < 0,2 were included in a multivariate analysis and a backward stepwise elimination was used. Colinear variables were not included together in the same model. A two tailed p-value < 0,05 was considered statistically significant. Direct comparison between treatment groups were performed with chi-square test or Fischer’s exact test, when appropriate, for categorical variables and a Student or Mann-Whitney Wilcoxon tests for continuous variables when appropriate. Mortality risk comparison used a logrank test. All statistical analyses were performed using SAS software, version 9.4. 3. Results 3.1 Patients’ characteristics Out of 655 patients identified in our department between 2010 and 2021, 246 met Sidney’s criteria for APS. Two hundred and seven patients had a TAPS and were included in the analysis (Figure 1). Characteristics at diagnosis and during follow-up of the 207 patients with TAPS are summarized in Table 1. The mean age at diagnostic was 53.3 years and 45.9% were male. APS was primary in 161 (77.8%) patients and SLE was present at diagnosis in 14 (6.8%) patients. There were 146 (70.5%) venous thromboembolic primary events and 68 (32.9%) arterial primary events. The APL positivity was single in 133 (64.3%) patients, double in 47 (22.7%) patients and triple in 27 (13%) patients. Twenty-seven (13%) patients were treated with APT only after diagnosis confirmation, 123 (59.4%) with VKA, and 45 (24.2%) with DOACs. Seven (3.4%) patients did not benefit of any antithrombotic drug. Mean follow-up was 5.2 years and median follow-up 3.5 years (Table 1). During follow-up, 28 (13.5%) recurrent thrombosis occurred (Table 1). Among them, 16 (57.1%) occurred to patients who were treated with VKA, 2 (7.2%) to patients treated with DOACs, 7 (25%) to patients treated with APT only and 3 (10.7%) to patients who had no antithrombotic treatment. Patients with VKA had 7 (43.8%) arterial recurrent thrombosis and 9 (56.3%) recurrent VTE. Patients with DOACs had 2 (100%) recurrent VTE. Patients treated with APT only or without antithrombotic treatment (n = 34) had 6 (60%) recurrent arterial thrombosis and 4 (40%) VTE events. The mean time from diagnosis to recurrence was 3.5 years and median time was 2 years. Death occurred in 12 (5.8%) patients, 7 (3.3%) under VKA, 4 (1.9%) under DOACs, 1 (0.5%) under APT only and none without treatment. Two patients died from hemorrhagic complications (both were in the VKA group) and none from recurrent thrombosis. 3.2 Risk factors for thrombotic recurrence Risk factors for recurrent thrombosis in multivariate analysis were SLE (HR = 4.27 [1.31 ; 13.92], p = 0.0160), diabetes mellitus (HR = 10.12 [3.37 ; 30.34], p < 0.0001), anticoagulation before the primary thrombotic event (HR = 3.70 [1.29 ; 10.61], p = 0.0147), previously known OAPS (HR = 7.70 [2.70 ; 21.96], p = 0.0001), no treatment after the primary thrombotic event (HR = 3.43 [1.06 ; 11.08], p = 0.0399) and APT alone after the primary thrombotic event (HR = 4.17 [1.53 ; 11.36], p = 0.0052). DOACs and VKA were not associated with recurrent thrombosis (Table 2). In the survival analysis, recurrent thrombosis were significantly higher in the group without antithrombotic treatment in comparison with those treated with DOACs (HR = 7.65 [1.18 ; 49.60]) (Figure 2). Recurrent thrombosis tended to be higher in the group without antithrombotic treatment as compared to those treated with VKA (HR = 3.88 [0.99 ; 15.27]) (Figure 2). No difference in the mortality rates were identified between the four treatment groups (Figure 3). 3.3 Clinical and biological characteristics according to initial antithrombotic drugs Clinical and biological characteristics according to initial oral anticoagulation (VKA versus DOACs (+/- APT)) are provided in Table 3. Patients with VKA were significantly younger and had more arterial thrombosis, LA positivity and triple APL positivity than those treated with DOACs (Table 3). Conversely, patients with DOACs were significantly older and had more venous thrombosis and single APL positivity. Factors associated with VKA versus DOACs prescription were the presence of LA (OR = 6.97 [1.42 ; 34.10], p < 0.0001), aCL positivity (OR = 3.23 [1.11 ; 9.38], p = 0.0314), aβ2GP1 IgM positivity (OR = 3.59 [1.25 ; 10.31], p = 0.0173), triple APL positivity (OR = 7.90 [1.35 ; 46.21], p = 0.0218) and the absence of primary venous thrombosis (OR = 0.01 [0.00 ; 0.25], p = 0.0036) (Table 4). 3.4 Bleedings Twenty-seven (13%) bleedings occurred during follow-up. Twenty-two (81.4%) patients were treated with VKA, 3 (11.1%) were treated with DOACs and 2 (7.5%) with APT only. Significantly more bleedings were found in VKA group as compared to DOACs (Table 3). 4. Discussion This monocentric longitudinal study based on real life data confirmed that APS is a high prothrombotic state that should be treated with long term anticoagulation considering the high recurrent thrombosis rate (30%) among patients without oral anticoagulation after initial thrombotic event. APT only and absence of antithrombotic drug after the primary thrombotic event were risk factors associated with recurrent thrombosis. VKA and DOACs were prescribed to 60% and 25% of TAPS patients respectively in our study whereas DOACs prescription is not recommended since RCT showed a higher recurrent thrombosis rate with DOACs (rivaroxaban or apixaban) versus VKA (warfarin). Pengo et al. found an increased risk for recurrent thrombosis in 120 TAPS patients with triple APL positivity when treated with rivaroxaban 20mg daily which ended the study prematurely 5 . Ordi-Ros et al. in their non-inferiority trial comparing warfarin to rivaroxaban 20mg daily in 190 TAPS patients also found a higher thrombotic recurrence risk for patients treated with rivaroxaban especially in the subgroup of patients with primary arterial thrombotic event. Their study included more than 60% of patients with triple APL positivity 6 . Two protocol changes were applied in Woller’s trial evaluating efficacy and safety of apixaban in 48 TAPS patients due to the high number of recurrent thrombosis in the apixaban group. Apixaban dosage was increased from 2.5mg twice daily to 5mg twice daily and patients with primary arterial thrombotic event were excluded. In this study which ended prematurely, 30% of patients were triple APL positive 7 . Considering these results, in 2019 the European society of cardiology (ESC) contraindicated the use of DOACs in APS regardless of the type of primary thrombosis and of the serologic profile 14 . Those recommendations were supported in 2020 by the American society of hematology (ASH) and the National Institute for Health and Care Excellence (NICE). Thereafter, a recent meta-analysis of 4 RCTs comparing DOACs to VKA including 474 TAPS patients, with 56.5% of triple-positive APS, did not find increased risk for VTE recurrence when treated with DOACs but confirmed the high recurrence rate of arterial thrombosis, especially stroke, regardless of history of arterial thrombosis and APL profile 17 . In our cohort, only 13% of patients were triple APL positive with 30% of missing data for LA detection. Interestingly, despite a shorter follow-up in DOACs group in comparison with VKA group, DOACs were not associated with recurrent thrombosis in the survival analysis in our study (Table 3). Neither the initial site of thrombosis (primary arterial thrombotic event) nor the APL profile (LA positivity or triple APL positivity) were predictive factors for recurrent thrombosis. Clinical and biological phenotype of TAPS patients treated by DOACs in our study seemed differ from previously cited studies 5–7 . DOACs were only prescribed to patients with venous primary thrombotic event (only one patient had both splenic artery and splenic vein thrombosis and had no recurrence with DOACs). Eighty percents (80%) of patients treated with DOACs had a single APL positivity and only 2% had triple APL positivity. DOACs prescription according to this APS profile was consistent with previous studies. A single arm prospective study published by Legault et al. followed 82 TAPS patients (none with triple APL positivity) with history of VTE treated with rivaroxaban 20mg daily during a mean follow-up of 19 months and found 4 (5%) recurrent thrombosis, 2 VTE and 2 arterial events with 3 of them being positive for LA. This recurrence rate was within the rates of recurrence of previous RCTs on warfarin use in TAPS 9 . Cohen et al. in their RCT which included solely TAPS with primary VTE event, compared 54 patients treated with rivaroxaban 20mg daily to 56 patients treated with warfarin and did not find any recurrent thrombosis in both groups after 6.5 months of follow-up. The triple APL positivity rate was of 28% in this study 8 . In the post-hoc analysis of TAPS patients in REMEDY I, REMEDY II and RECOVER trials, Goldhaber et al. compared 71 patients treated with dabigatran to 80 patients treated with VKA and did not find differences in the recurrence of VTE with 4.2% in the dabigatran group and 5% in the VKA group 18 . Two (4%) recurrent thrombosis occurred in the DOACs group during follow-up in our study. This recurrent thrombosis rate seemed to be close to those found in the literature. Doyle et al. retrospectively analyzed 82 TAPS patients with primary VTE event treated with DOACs and found 4 (5%) recurrent thrombosis (2 arterial events and 2 VTE) with a median follow-up of 9 years 19 . Liu et al. retrospectively compared 143 TAPS patients with prior arterial or VTE event and with single APL positivity treated with VKA or DOACs and found no difference in the recurrence rate (6/91 (6.5%) patients in the VKA group and 3/52 (6%) patients in the DOACs group) with a median follow-up of 4.6 years 20 . Our results are also showing similar recurrent thrombosis rates as Brianna et al. who retrospectively compared 166 single or double APS patients, 54 (32.5%) of them being treated with DOACs to 24 triple APS patients among whom 5 (21%) being treated with DOACs. There were 30 (15.8%) recurrent thrombosis, 6 of them being in the triple APS group. Three recurrent thrombosis occurred in DOACs treated patients and two of them were with triple APS 21 . In our study, 28 recurrent thrombosis occurred, 5 of the being in the triple APS group. Two recurrent thrombosis occurred in DOACs treated patients none of them having triple APS positivity. Thus, in 2019, the EULAR suggested the possibility of using DOACs in patients already on DOACs for a primary VTE event in whom a single or double APL positivity was found without the presence of LA 4 . Similarly, the 2020 ISTH guidelines, the 2020 BSH (British Society of Hematology) guidelines and the 2020 recommendations of the 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends contraindicated the use of DOACs in patients with APS and arterial thrombosis or triple APL positivity, taking into consideration their use in patients with primary VTE event and single or double APL positivity 10,11,22 . Our results based on real life data confirmed the safety and efficiency of this treatment strategy. All patients with TAPS treated with DOACs should also be reported to the ISTH supported registry (ClinicalTrials.gov Identifier: NCT04262492) to provide real-life data at a larger scale 10 . Among cardiovascular risk factors collected, diabetes mellitus was significantly associated to recurrent thrombosis in our study which is concordant with Bazzan et al 23 . Hypertension, dyslipidemia and smoking were also associated with arterial events in the literature 24,25 . Previously known SLE and OAPS were risk factors for recurrent thrombosis in our study. Patients with SLE and APL positivity had a higher risk of first thrombotic occurrence in the literature 26,27 but evidence was lacking regarding secondary APS with SLE and higher recurrent thrombosis risk. In Qi et al. cluster analysis of a prospective cohort of 383 APS and asymptomatic APL carriers (among whom 219 with TAPS), cluster 1 which included 44.2% patients with SLE and 57.2% patients with triple APL positivity showed high thrombotic arterial rate (42.8%) and deep venous thrombosis rate (33.3%). Contrary to our result, women with obstetric morbidity were aggregated in cluster 3 in which the proportions of arterial thrombosis (3.6%) and deep venous thrombosis (16.9%) were the lowest 28 . As in previous studies evaluating TAPS, bleeding risk was similar between DOACs and VKA groups in our Cox model 20,29,30 while DOACs exhibits a safer profile with a lower incidence of cerebral bleeding in nonvalvular atrial fibrillation 31 and VTE 32 . A lack of statistical power for this safety endpoint may explain this result in TAPS studies as the recent meta-analysis by Khairani et al. did not show any difference between DOACs and VKA 17 . We report real life data on the use of oral anticoagulation for the treatment of TAPS. To our knowledge, this study is the largest retrospective longitudinal cohort evaluating the risks factors of recurrent thrombosis in TAPS and comparing VKA and DOACs, confirming some previously identified risk factors for recurrent thrombosis in TAPS (diabetes mellitus, no antithrombotic treatment or APT only after the primary thrombotic event) and also identifying new ones (SLE, OAPS). The retrospective study is a limitation of this study as some data were missing, including LA detection that could impact a proper APL profile characterization. Another limitation of our work is that we failed in verifying patient adherence to antithrombotic treatments. The INR control at the time of recurrence for VKA treated patients was unknown for most patients. The impact of the new 2023 APS criteria on the way to treat TAPS is yet to be seen 33 . 5. Conclusion Our study confirmed some previously identified risk factors for recurrent thrombosis in TAPS and also identified new ones. DOACs were not associated with higher recurrent thrombosis as compared to VKA. Neither the initial site of thrombosis nor the APL profile were predictive of recurrent thrombosis due to oral anticoagulation prescription directed by clinical and biological TAPS profile. In this real-life cohort, DOACs were only prescribed in patients with single or double APL positivity and primary VTE event. VKA were prescribed in patients with triple APL positivity or primary arterial event. The place of DOACs in TAPS remains to be clarified by prospective studies, especially after the publication of the new APS criteria presented as oral communication in Philadelphia in November 2022 34 . Abbreviations APS = antiphospholipid syndrome APL = antiphospholipid antibodies TAPS = thrombotic antiphospholipid syndrome OAPS = obstetrical antiphospholipid syndrome SLE = systemic lupus erythematosus VTE = venous thromboembolism RCT = randomized controlled trial DVT = deep vein thrombosis APT = antiplatelet therapy DOACs = direct oral anticoagulants VKA = vitamin K antagonist LA = lupus anticoagulant aCL = anticardiolipin antibodies aβ2GPI = anti-β2-glycoprotein-I antibodies NET = neutrophil extracellular traps INR = international normalized ratio ESC = European society of cardiology BSH = British Society of Hematology ISTH = International Society on Thrombosis and Haemostasis ASH =American Society of Hematology NICE = National Institute for Health and Care Excellence NA = not applicable NS = not significant HR = hazard ratio OR = odds ratio SD = standard deviation References Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost . 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x Knight JS, Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol . 2022;44(3):347-362. doi:10.1007/s00281-022-00916-w Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med . 2018;378(21):2010-2021. doi:10.1056/NEJMra1705454 Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis . 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213 Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood . 2018;132(13):1365-1371. doi:10.1182/blood-2018-04-848333 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med . 2019;171(10):685-694. doi:10.7326/M19-0291 Woller SC, Stevens SM, Kaplan D, et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv . 2022;6(6):1661-1670. doi:10.1182/bloodadvances.2021005808 Cohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol . 2016;3(9):e426-436. doi:10.1016/S2352-3026(16)30079-5 Legault K, Blostein M, Carrier M, et al. A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot Feasibility Stud . 2020;6(1):52. doi:10.1186/s40814-020-00594-1 Cohen H, Cuadrado MJ, Erkan D, et al. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus . 2020;29(12):1571-1593. doi:10.1177/0961203320950461 Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost . 2020;18(9):2126-2137. doi:10.1111/jth.14935 Bouzillé G, Sylvestre E, Campillo-Gimenez B, et al. An Integrated Workflow For Secondary Use of Patient Data for Clinical Research. Stud Health Technol Inform . 2015;216:913. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Anticoagulation the S on C of. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost . 2015;13(11):2119-2126. doi:10.1111/jth.13140 Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J . 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405 McCormack T, Harrisingh MC, Horner D, Bewley S. Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing. BMJ . 2020;369:m1565. doi:10.1136/bmj.m1565 Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv . 2020;4(19):4693-4738. doi:10.1182/bloodadvances.2020001830 Khairani CD, Bejjani A, Piazza G, et al. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. J Am Coll Cardiol . 2023;81(1):16-30. doi:10.1016/j.jacc.2022.10.008 Goldhaber SZ, Eriksson H, Kakkar A, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER TM II, and RE-MEDY TM . Vasc Med . 2016;21(6):506-514. doi:10.1177/1358863X16668588 Doyle AJ, Hunt BJ, Danaee A, et al. Direct oral anticoagulant use in patients with antiphospholipid syndrome and unprovoked venous thromboembolism: a single centre experience. Br J Haematol . 2021;195(2):276-278. doi:10.1111/bjh.17634 Liu A, Rupani KV, Naymagon L. Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome. Eur J Haematol . 2022;109(1):69-74. doi:10.1111/ejh.13770 Bakow BR, Phung Q, Rabinovich D, Olszewski AJ, Reagan JL. Choice of anticoagulation in patients with low risk antiphospholipid syndrome. J Thromb Thrombolysis . Published online May 23, 2023. doi:10.1007/s11239-023-02826-6 Arachchillage DRJ, Gomez K, Alikhan R, et al. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47–58): use of direct acting oral anticoagulants. Br J Haematol . 2020;189(2):212-215. doi:10.1111/bjh.16308 Bazzan M, Vaccarino A, Stella S, et al. Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study). Lupus . 2016;25(5):479-485. doi:10.1177/0961203315617538 Taraborelli M, Reggia R, Dall’Ara F, et al. Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. J Rheumatol . 2017;44(8):1165-1172. doi:10.3899/jrheum.161364 Niznik S, Rapoport MJ, Avnery O, et al. Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up. Front Immunol . 2022;13:843718. doi:10.3389/fimmu.2022.843718 Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum . 2009;61(1):29-36. doi:10.1002/art.24232 Farina N, Abdulsalam R, McDonnell T, et al. Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events. Rheumatology . Published online October 13, 2022:keac596. doi:10.1093/rheumatology/keac596 Qi W, Zhao J, Huang C, et al. Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study. Arthritis Res Ther . 2022;24(1):140. doi:10.1186/s13075-022-02814-w Williams B, Saseen JJ, Trujillo T, Palkimas S. Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome. J Thromb Thrombolysis . 2022;54(1):67-73. doi:10.1007/s11239-021-02587-0 Malec K, Broniatowska E, Undas A. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. Lupus . 2020;29(1):37-44. doi:10.1177/0961203319889156 Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med . 2011;365(10):883-891. doi:10.1056/NEJMoa1009638 EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med . 2012;366(14):1287-1297. doi:10.1056/NEJMoa1113572 Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol . 2023;n/a(n/a). doi:10.1002/art.42624 Barbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care Res . 2021;73(10):1490-1501. doi:10.1002/acr.24520 Tables Table 1 : Characteristics at diagnosis and during follow-up in 207 patients with TAPS fulfilling international Sydney criteria Parameters Overall population N = 207 Patients with thrombotic recurrence N= 28 Patients without thrombotic recurrence N = 179 Clinical characteristics and comorbidities at diagnosis Age, years, mean ± SD (median) 53.3 ± 17.7 (54.8) 48.0 ± 18 (48.4) 54.2 ± 17.5 (55.1) Male gender 95 (45.9%) 4 (14.3%) 91 (50.8%) History of tobacco use 93 (45.1%) 15 (53.6%) 78 (43.8%) Hypertension 59 (28.5%) 9 (32.1%) 50 (27.9%) Diabetes mellitus 7 (3.4%) 4 (14.3%) 3 (1.7%) Dyslipidemia 42 (20.3%) 7 (25.0%) 35 (19.6%) Obesity 24 (11.6%) 4 (14.3%) 20 (11.2%) Autoimmune disease 46 (22.2%) 10 (35.7%) 36 (20.1%) SLE 14 (6.8%) 5 (17.9%) 9 (5.0%) Arterial morbidity 36 (17.4%) 2 ( 7.1%) 34 (19.0%) Venous morbidity 49 (23.7%) 3 (10.7%) 46 (25.7%) Pregnancy morbidity 23 (11.1%) 9 (32.1%) 14 (7.8%) Previously known OAPS 6 (2.9%) 4(14.2) 2 (1.1%) Primary thrombotic event * Arterial thrombosis 68 (32.9%) 11 (39.3%) 57 (31.8%) Ischemic stroke 46 (22.2%) 6 (21.4%) 40 (22.3%) Myocardial infarction 6 (2.9%) 1 ( 3.6%) 5 (2.8%) Other 17 (8.2%) 3 (10.7%) 14 (7.8%) Venous thrombosis 146 (68.1%) 19 (67.9%) 127 (70.9%) Proximal deep vein thrombosis 74 (35.7%) 11 (39.3%) 63 (35.2%) Pulmonary embolism 91 (44.0%) 12 (42.9%) 79 (44.1%) Other 18 (8.7%) 0 (0.0%) 18 (10.1%) Biological characteristics at diagnosis LA detected 56 (27.1%) 8 (28.6%) 48 (26.8%) aCL positive 113 (54.6%) 21 (75.0%) 92 (51.4%) aCL IgG positive 73 (36.9%) 13 (54.2%) 60 (34.5%) aCL IgM positive 50 (25.6%) 7 (30.4%) 43 (25.0%) aβ2GP1 positive 137 (66.2%) 17 (60.7%) 120 (67.0%) aβ2GP1 IgG positive 78 (41.7%) 8 (40.0%) 70 (41.9%) aβ2GP1 IgM positive 68 (37.0%) 6 (30.0%) 62 (37.8%) Single positivity 133 (64.3%) 15 (53.6%) 118 (65.9%) Double positivity 47 (22.7%) 8 (28.6%) 39 (21.8%) Triple positivity 27 (13.0%) 5 (17.9%) 22 (12.3%) Medications before diagnosis APT 32 (15.5%) 3 (10.7%) 29 (16.2%) Anticoagulant drugs 7 (3.4%) 3 (10.7%) 4 (2.2%) Statin 27 (13.0%) 1 (3.6%) 26 (14.5%) Hydroxychloroquine 5 (2.4%) 2 (7.1%) 3 (1.6%) Vitamin D 9 (4.3%) 2 (7.1%) 7 (3.9%) Antihypertensive 60 (29.0%) 9 (32.1%) 51 (28.5%) Oral estroprogestative contraception 16 (7.7%) 1 (3.6%) 15 (8.4%) Oral progestative contraception 3 (1.4%) 0 (0.0%) 3 (1.7%) Antithrombotic drugs after the primary thrombotic event No antithrombotic drug 7 (3.4%) 3 (10.7%) 4(2.2%) APT only 27 (13.0%) 7 (25.0%) 20 (11.2%) VKA +/- APT 123 (59.4%) 16 (57.1%) 107 (59.8%) DOACs +/- APT 50 (24.2%) 2 (7.1%) 48 (26.8%) Follow-up Follow-up, years, mean ± SD (median) 5.2 ± 4.9 (3.5) 10.0 ± 6.6 (10) 4.4 ± 4.1 (3.2) Time to recurrence, years, mean ± SD (median) NA 3.5 ± 3.5 (2) NA Death 12 (5.8%) 3 (10.7%) 9 (5%) * Patients may have experienced more than one thrombotic event leading to TAPS diagnosis. TAPS = thrombotic antiphospholipid syndrome ; OAPS = obstetrical antiphospholipid syndrome ; SLE = systemic lupus erythematosus ; aβ2GP1 = Anti-β-2-glycoprotein-1 ; aCL = Anti-cardiolipin ; LA = Lupus anticoagulant ; APT = antiplatelet therapy ; VKA = vitamin K antagonist ; DOACs = direct oral anticoagulants ; SD = standard deviation ; NA = not applicable Table 2 : Risk factors for recurrent thrombosis in 207 patients with TAPS Parameters Thrombotic recurrence (n = 28) No thrombotic recurrence (n = 179) Univariate HR 95% CI Univariate p value Multivariate HR 95% CI Multivariate p value Clinical characteristics and comorbidities Male gender 4 (14.2%) 91 (50.8%) 0.27 [0.09 ; 0.77] 0.0151 NS History of tobacco use 15 (53.6%) 78 (43.8%) 1.21 [0.58 ; 2.53] 0.6151 Hypertension 9 (32.1%) 50 (27.9%) 1.41 [0.64 ; 3.09] 0.3942 Diabetes mellitus 4 (14.3) 3 (1.3%) 4.74 [1.68 ; 13.38] 0.0033 10.12 [3.37 ; 30.34] < 0.0001 Dyslipidemia 7 (25%) 35 (19.6%) 1.41 [0.62 ; 3.41] 0.3942 Obesity 4 (14.3%) 20 (11.2%) 1.35 [0.46 ; 3.99] 0.5861 Autoimmune disease 10 (35.7%) 36 (20.1%) 1.83 [0.84 ; 3.98] 0.1259 § SLE 5 (17.9%) 9 (5.0%) 3.56 [1.23 ; 10.29] 0.0190 4.27 [1.31 ; 13.92] 0.0160 Arterial morbidity 2 (7.1%) 34 (19.0%) 0.41 [0.10 ; 1.68] 0.2130 Venous morbidity 3 (10.7%) 46 (25.7%) 0.45 [0.14 ; 1.45] 0.1784 NS Pregnancy morbidity 9 (32.1%) 14 (7.8%) 2.89 [1.37 ; 6.14] 0.0056 Previously known OAPS 4 (14.2) 2(1.1%) 4.95 [1.88 ; 13.00] 0.0012 7.70 [2.70 ; 21.96] 0.0001 Primary thrombotic event* Arterial thrombosis 11 (39.3%) 57 (31.8%) 1.00 [0.45 ; 2.23] 0.9946 Ischemic stroke 6 (21.4%) 40 (22.3%) 0.75 [0.30 ; 1.87] 0.5304 Myocardial infarction 1 (3.6%) 5 (2.8%) 0.57 [0.07 ; 5.00] 0.6153 Other 3 (10.7%) 14 (7.8%) 1.33 [0.36 ; 4.95] 0.6660 Venous thrombosis 19 (67.9%) 127 (70.9%) 1.14 [0.50 ; 2.63] 0.7547 Proximal deep vein thrombosis 11 (39.3%) 63 (35.2%) 1.17 [0.56 ; 2.46] 0.6821 Pulmonary embolism 12 (42.9%) 79 (44.1%) 1.16 [0.55 ; 2.43] 0.6929 Other 0 (0.0%) 18 (10.1%) 0.22 [0.01 ; 3.82] 0.3002 Biological characteristics at diagnosis LA detected 8 (28.6%) 48 (26.8%) 1.07 [0.36 ; 3.17] 0.4401 aCL positive 21 (75.0%) 92 (51.4%) 2.09 [0.89 ; 4.90] 0.0906 NS aCL IgG positive 13 (54.2%) 60 (34.5%) 1.50 [0.66 ; 3.37] 0.3302 aCL IgM positive 7 (30.4%) 43 (25.0%) 1.58 [0.65 ; 3.82] 0.3123 aβ2GP1 positive 17 (60.7%) 120 (67.0%) 0.97 [0.45 ; 2.08] 0.9327 aβ2GP1 IgG positive 8 (40.0%) 70 (41.9%) 0.97 [0.40 ; 2.33] 0.9456 aβ2GP1 IgM positive 6 (30.0%) 62 (37.8%) 0.66 [0.25 ; 1.74] 0.4040 Single positivity 15 (53.6%) 118 (65.9%) 0.69 [0.33 ; 1.44] 0.3219 Double positivity 8 (28.6%) 39 (21.8%) 1.26 [0.55 ; 2.90] 0.5868 Triple positivity 5 (17.9%) 22 (12.3%) 1.42 [0.56 ; 3.59] 0.4586 Medications before diagnosis APT 3 (10.7%) 29 (16.2%) 0.74 [0.23 ; 2.41] 0.6154 Anticoagulant drugs 3 (10.7%) 4 (2.2%) 2.59 [1.02 ; 6.55] 0.0449 3.70 [1.29 ; 10.61] 0.0147 Statin 1 (3.6%) 26 (14.5%) 0.29 [0.04 ; 2.16] 0.2255 Vitamin D 2 (7.1%) 7 (3.9%) 2.12 [0.43 ; 10.42] 0.3537 Antihypertensive 9 (32.1%) 51 (28.5%) 1.45 [0.66 ; 3.20] 0.3556 Oral oestroprogestative contraception 1 (3.6%) 15 (8.4%) 0.27 [0.03 ; 2.12] 0.2141 Oral progestative contraception 0 (0.0%) 3 (1.7%) 0.48 [0.03 ; 8.25] 0.6099 Drugs after first thrombotic event No antithrombotic drug 3 (10.7%) 4 (2.2%) 5.14 [2.17 ; 12.19] 0.0002 3.43 [1.06 ; 11.08] 0.0399 APT only 7 (25.0%) 20 (11.2%) 2.23 [0.94 ; 5.27] 0.0685 4.17 [1.53 ; 11.36] 0.0052 VKA +/- APT 14 (50.0%) 107 (59.8%) 0.62 [0.29 ; 1.32] 0.2172 DOACs +/- APT 2 (7.1%) 48 (26.8%) 0.38 [0.09 ; 1.59] 0.1841 NS Statin 5 (17.8%) 50 (27.9%) 0.51 [0.19 ; 1.36] 0.1765 NS D vitamin 2 (7.1%) 16 (8.9%) 0.85 [0.20 ; 3.72] 0.8314 Hydroxychloroquine 3 (10.7%) 11 (6.1%) 1.22 [0.33 ; 4.48] 0.7629 Following variables were included in the Cox model for multivariate analysis : Previously known diabetes mellitus, previously known SLE, venous morbidity, previously known OAPS, arterial thrombosis at diagnosis, aβ2GP1, aCL, LA, anticoagulant drugs taken before diagnosis, no antithrombotic drug after diagnosis, APT only after diagnosis, VKA +/- APT after diagnosis, DOACs +/-APT after diagnosis and statin after diagnosis. Stepwise elimination was then made. aβ2GP1 = Anti-β-2-glycoprotein-1 ; aCL = Anti-cardiolipin ; LA = Lupus anticoagulant ; SLE = systemic lupus erythematosus OAPS = obstetrical antiphospholipid syndrome ; TAPS = thrombotic antiphospholipid ; APT = antiplatelet therapy ; VKA = vitamin K Antagonist ; DOACs = direct anticoagulants ; HR = hazard ratio ; CI = confidence interval ; syndrome ; NS = not significant. * Patients may have experienced more than one thrombotic event leading to TAPS diagnosis. § Colinear variables weren’t included together in the same model. Table 3. Clinical and biological characteristics according to initial oral anticoagulation (VKA versus DOACs) in 173 TAPS patients Parameters VKA+/-APT n= 123 DOACs +/-APT n= 50 p-value Clinical characteristics and comorbidities at diagnosis Age, years, mean ± SD (median) 51.8 ± 17.5 (53.4) 61.1 ± 16.2 (62.9) 0.0014 Male gender 56 (45.5%) 22 (44%) 0.8547 History of tobacco use 62 (50.8%) 15 (30.0%) 0.0127 Hypertension 38 (30.9%) 16 (32.0%) 0.8869 Diabetes mellitus 6 (4.9%) 1 (2.0%) 0.6747 Dyslipidemia 26 (21.1%) 11 (22.0%) 0.9003 Obesity 16 (13.0%) 6 (12.0%) 0.8568 Autoimmune disease 32 (26.0%) 7 (14.0%) 0.0864 Systemic lupus erythematosus associated 9 (7.3%) 2 (4.0%) 0.5143 Arterial morbidity 24 (19.5%) 8 (16.0%) 0.5897 Venous morbidity 28 (22.8%) 16 (32.0%) 0.2061 Pregnancy morbidity 14 (11.4%) 2 (4.0%) 0.1571 Primary thrombotic event * Arterial thrombosis 52 (42.3%) 1 (2.0%) < 0.0001 Ischemic stroke 37 (30.1%) 0 (0.0%) < 0.0001 Myocardial infarction 6 (4.9%) 0 (0.0%) 0.1833 Other 12 (9.8%) 1 (2.0%) 0,0698 Venous thrombosis 74 (60.2%) 50 (100.0%) < 0.0001 Proximal DVT 34 (27.6%) 25 (50.0%) 0.0049 Pulmonary embolism 45 (36.6%) 37 (74.0%) < 0.0001 Other 13 (10.6%) 4 (8.0%) 0.7807 Biological characteristics at diagnosis Lupus anticoagulant detected 42 (34.1%) 2 (4.0%) < 0.0001 aCL positive 69 (56.1%) 25 (50.0%) 0.4655 aCL IgG positive 50 (43.1%) 14 (28.6%) 0.0800 aCL IgM positive 29 (25.4%) 12 (24.5%) 0.8981 aβ2GP1 positive 90 (73.2%) 33 (66.0%) 0.3456 aβ2GP1 IgG positive 52 (48.6%) 20 (40.8%) 0.3655 aβ2GP1 IgM positive 47 (45.2%) 15 (30.6%) 0.0865 Single positivity 68 (55.3%) 40 (80.0%) 0.0023 Double positivity 32 (26.0%) 9 (18.0%) 0.2610 Triple positivity 23 (18.7%) 1 (2.0%) 0.0040 Secondary events during follow-up Follow-up, years, mean ± SD (median) 5.5 ± 4.5 (4.1) 2.6 ± 1.7 (2.3) < 0.0001 Time to recurrent thrombosis, years, mean ± SD (median) 3.6 ± 3.7 (2.4) 1.2 ± 0.8 (1.2) NA Recurrent thrombosis 16 (13.0%) 2 (4.0%) 0.0786 Arterial thrombosis 7 (43.8%) 2 (100.0%) 0.4706 Ischemic stroke 5 (71.4%) 1 (50.0%) NA Myocardial infarction 0 0 NA Other 2 (28.6%) 1 (50.0%) NA Venous thrombosis 9 (56.3%) 0 NA Isolated proximal DVT 1 (11.1%) 0 NA Pulmonary embolism +/-DVT 7 (77.8%) 0 NA Other 1 (11.1%) 0 NA Bleedings 22 (17.9%) 3 (6%) 0,0438 Major bleedings 17 (13.8%) 3 (6%) 0,1447 Non major bleedings 5 (4.1%) 0 0,3231 Death 7 (5.7%) 4 (8.0%) 0.7317 Treatment change 37 (30.1%) 18 (36.0%) 0.4486 TAPS = thrombotic antiphospholipid syndrome; APT = antiplatelet therapy ; VKA = vitamin K antagonist ; DOACs = direct oral anticoagulants ; SLE = systemic lupus erythematosus ; DVT = deep vein thrombosis ; aβ2GP1 = Anti-β-2-glycoprotein-1 ; aCL = Anti-cardiolipin ; LA = Lupus anticoagulant ; NA = not applicable ; SD = standard deviation. * Patients may have experienced more than one thrombotic event leading to TAPS diagnosis. Table 4 : Factors associated with the initial prescription of VKAs versus DOACs in 173 TAPS patients : Parameters VKA +/- APT (n = 123) DOACs +/- APT (n = 50) Univariate OR 95% CI Univariate p value Multivariate OR 95% CI Multivariate p value Clinical characteristics and comorbidities at diagnosis Male gender 56 (45.5%) 22 (44%) 1.06 [0.55 ; 2.06] 0.8547 History of tobacco use 62 (50.8%) 15 (30.0%) 2.41 [1.20 ; 4.86] 0.0139 NS Hypertension 38 (30.9%) 16 (32.0%) 0.95 [0.47 ; 1.93] 0.8864 Diabetes mellitus 6 ( 4.9%) 1 (2.0%) 2.51 [0.29 ; 21.42] 0.3994 Dyslipidemia 26 (21.1%) 11 (22.0%) 0.95 [0.43 ; 2.11] 0.8997 Obesity 16 (13.0%) 6 (12.0%) 1.10 [0.40 ; 2.99] 0.8569 Autoimmune disease 32 (26.0%) 7 (14.0%) 2.16 [0.88 ; 5.28] 0.0916 SLE 9 (7.3%) 2 (4.0%) 1.89 [0.39 ; 9.10] 0.4246 Arterial morbidity 24 (19.5%) 8 (16.0%) 1.27 [0.53 ; 3.06] 0.5903 Venous morbidity 28 (22.8%) 16 (32.0%) 0.63 [0.30 ; 1.30] 0.2080 Pregnancy morbidity 14 (11.4%) 2 (4.0%) 3.08 [0.67 ; 14.09] 0.1466 NS Initial clinical event * Arterial thrombosis 52 (42.3%) 1 (2.0%) 37.08 [4.96 ; 277.13] 0.0004 NS Ischemic stroke 37 (30.1%) 0 (0.0%) 43.79 [2.54 ; 756.34] 0.0093 § Myocardial infarction 6 ( 4.9%) 0 (0.0%) 5.59 [0.25 ; 127.45] 0.2804 Other 12 (9.8%) 1 (2,0%) 4.03 [0.68 ; 23.86] 0.1244 § Venous thrombosis 74 (60.2%) 50 (100.0%) 0.01 [0.00 ; 0.25] 0.0037 0.01 [0.00 ; 0.25] 0.0036 Proximal DVT 34 (27.6%) 25 (50.0%) 0.38 [0.19 ; 0.75] 0.0056 § Pulmonary embolism 45 (36.6%) 37 (74.0%) 0.20 [0.10 ; 0.42] <0.0001 § Other 13 (10.6%) 4 (8.0%) 1.36 [0.42 ; 4.39] 0.6081 Biological characteristics at diagnosis LA detected 42 (34.1%) 2 (4.0%) 7.96 [1.64 ; 38.61] < 0.0001 6.97 [1.42 ; 34.10] < 0.0001 aCL positive 69 (56.1%) 25 (50.0%) 1.28 [0.66 ; 2.47] 0.4659 3.23 [1.11 ; 9.38] 0.0314 aCL IgG positive 50 (43.1%) 14 (28.6%) 1.89 [0.92 ; 3.89] 0.0823 § aCL IgM positive 29 (25.4%) 12 (24.5%) 1.05 [0.48 ; 2.28] 0.8987 aβ2GP1 positive 90 (73.2%) 33 (66.0%) 1.40 [0.69 ; 2.85] 0.3466 aβ2GP1 IgG positive 52 (48.6%) 20 (40.8%) 1.37 [0.69 ; 2.72] 0.3662 aβ2GP1 IgM positive 47 (45.2%) 15 (30.6%) 1.87 [0.91 ; 3.84] 0.0887 3.59 [1.25 ; 10.31] 0.0173 Single positivity 68 (55.3%) 40 (80.0%) 0.31 [0.14 ; 0.67] 0.0031 NS Double positivity 32 (26.0%) 9 (18.0%) 1.60 [0.70 ; 3.66] 0.2639 Triple positivity 23 (18.7%) 1 (2.0%) 11.26 [1.48 ; 85.74] 0.0194 7.90 [1.35 ; 46.21] 0.0218 Two multivariate analysis were performed. Following variables were included in the first cox model: history of tobacco use, pregnancy morbidity, arterial thrombosis, venous thrombosis, LA detected, aCL, aβ2GP1 IgM. Stepwise elimination was then made. Following variables were included in the second cox model: history of tobacco use, pregnancy morbidity, arterial thrombosis, venous thrombosis, single positivity and triple positivity. Stepwise regression was then made. § Colinear variables weren’t included together in the same model. TAPS = thrombotic antiphospholipid syndrome ; APT = antiplatelet therapy ; VKA = vitamin K antagonist ; DOACs = direct oral anticoagulants ; SLE = systemic lupus erythematosus ; DVT = deep vein thrombosis ; aβ2GP1 = Anti-β-2-glycoprotein-1 ; aCL = Anti-cardiolipin ; LA = Lupus anticoagulant ; OR = odds ratio ; CI = confidence interval ; NS = not significant. * Patients may have experienced more than one thrombotic event leading to TAPS diagnosis. Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3951851","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":272509177,"identity":"4f3842e1-257a-4cf0-ab0e-d4510aab5f57","order_by":0,"name":"LEMESLE Guillaume","email":"data:image/png;base64,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","orcid":"","institution":"Hôpital Pontchaillou, Centre Hospitalo - Universitaire de Rennes, Rennes, France","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"LEMESLE","middleName":"","lastName":"Guillaume","suffix":""},{"id":272509610,"identity":"634d6928-cb12-49db-97b5-9df55c2bc5d3","order_by":1,"name":"BOUZILLE Guillaume","email":"","orcid":"","institution":"INSERM, U1099, Rennes, F-35000, France","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"BOUZILLE","middleName":"","lastName":"Guillaume","suffix":""},{"id":272509611,"identity":"be6aa37d-4903-4286-9fde-65420acb504b","order_by":2,"name":"BELHOMME Nicolas","email":"","orcid":"","institution":"Hôpital Pontchaillou, Centre Hospitalo - Universitaire de Rennes, Rennes, France","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"BELHOMME","middleName":"","lastName":"Nicolas","suffix":""},{"id":272509612,"identity":"128ead71-8cc9-4ad1-bdeb-ad5336ea1d54","order_by":3,"name":"ROUSSEAU Chloé","email":"","orcid":"","institution":"Hôpital Pontchaillou, Centre Hospitalo - Universitaire de Rennes, Rennes, France","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"ROUSSEAU","middleName":"","lastName":"Chloé","suffix":""},{"id":272509613,"identity":"f3b37844-565b-4eb9-998d-f60b476e22b4","order_by":4,"name":"DUMONTET Erwan","email":"","orcid":"","institution":"Hôpital Pontchaillou, Centre Hospitalo - Universitaire de Rennes, Rennes, France","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"DUMONTET","middleName":"","lastName":"Erwan","suffix":""},{"id":272509614,"identity":"0237a141-dbc0-48b1-b134-e5c0416460bc","order_by":5,"name":"GOUIN Isabelle","email":"","orcid":"","institution":"Hôpital Pontchaillou, Centre Hospitalo - Universitaire de Rennes, Rennes, France","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"GOUIN","middleName":"","lastName":"Isabelle","suffix":""},{"id":272509615,"identity":"d41d5b3d-b700-4287-ac1a-f9c9f5b3712e","order_by":6,"name":"LESCOAT Alain","email":"","orcid":"","institution":"Hôpital Pontchaillou, Centre Hospitalo - Universitaire de Rennes, Rennes, France","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"LESCOAT","middleName":"","lastName":"Alain","suffix":""},{"id":272509616,"identity":"2287cc0e-1b2a-46b5-acff-3f4d990d0b5d","order_by":7,"name":"BALLERIE Alice","email":"","orcid":"","institution":"Hôpital Pontchaillou, Centre Hospitalo - Universitaire de Rennes, Rennes, France","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"BALLERIE","middleName":"","lastName":"Alice","suffix":""}],"badges":[],"createdAt":"2024-02-12 20:07:08","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false,"coiExplicitlySet":false},"doi":"10.21203/rs.3.rs-3951851/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3951851/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":51077523,"identity":"50b290be-b43a-494e-a2cc-9460cc598b00","added_by":"auto","created_at":"2024-02-13 18:46:34","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":266786,"visible":true,"origin":"","legend":"\u003cp\u003eFlow-Chart\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-3951851/v1/fe0cb5eaad3462b6840399ee.png"},{"id":51077522,"identity":"b12ddb3b-2535-44b3-91d5-7c23cce75c55","added_by":"auto","created_at":"2024-02-13 18:46:32","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":257635,"visible":true,"origin":"","legend":"\u003cp\u003eIncidence curves of recurrent thrombosis according to initial treatment in 207 patients with TAPS ; A. Survival analysis with competitive risk using a Cox model ; B. All HR between each treatment group\u003c/p\u003e","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3951851/v1/a969279d379b10f1cd2c8f2b.jpg"},{"id":51077524,"identity":"ab250640-9252-4b1f-b48f-a584dec496d2","added_by":"auto","created_at":"2024-02-13 18:46:34","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":89235,"visible":true,"origin":"","legend":"\u003cp\u003eMortality in each treatment group using Kaplan Meier curves in 207 patients with TAPS\u003c/p\u003e\n\u003cp\u003eAPT = antiplatelet therapy ; VKA = vitamin K antagonist ; DOACs = direct oral anticoagulants ; TAPS = thrombotic antiphospholipid syndrome.\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-3951851/v1/acf7823f5095a696fc532561.png"},{"id":51077526,"identity":"59615c92-0abf-4110-bab9-e39ff27fe3d7","added_by":"auto","created_at":"2024-02-13 18:46:41","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1519031,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3951851/v1/3ef4756b-7d76-4b63-b4eb-ab31bc977784.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cstrong\u003eRisk factors for recurrent thrombosis and comparison of DOACs vs VKA in selected thrombotic antiphospholipid syndrome\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eAntiphospholipid syndrome (APS) is an auto-immune disease characterized by venous, arterial or microvascular thrombosis and/or pregnancy morbidity associated to persistence of antiphospholipid antibodies (APL), namely lupus anticoagulant (LA), IgG and IgM anticardiolipin (aCL), and IgG and IgM anti-\u0026beta;2-glycoprotein-I antibodies (a\u0026beta;2GPI) \u003csup\u003e1\u003c/sup\u003e. The pathophysiology of thrombotic antiphospholipid syndrome (TAPS) is thought to involve the generation APL which create a prothrombotic state through different pathways; including a) binding to endothelial cells b) increasing tissue factor secretion, c) triggering platelet aggregation, d) increasing neutrophil extracellular traps (NET) formation, diminishing their clearance and inducing complement activation \u003csup\u003e2\u003c/sup\u003e. APS is considered primary APS when isolated or secondary APS when associated with other auto-immune diseases especially systemic lupus erythematosus (SLE). Obstetrical antiphospholipid syndrome (OAPS) is defined by obstetric event in the absence of any thrombotic manifestations. \u003c/p\u003e\n\u003cp\u003ePatients with TAPS are at high risk for recurrent thrombosis and are usually treated with long-term oral anticoagulation using vitamin K antagonist (VKA) in regards of recent guidelines \u003csup\u003e3\u003c/sup\u003e. Risk stratification studies highlight risks of recurrent thrombosis according to clinical and biological APS phenotypes \u003csup\u003e4\u003c/sup\u003e. Thus, patients with arterial thrombosis, patients with double or triple APL positivity as well as patients with persistent LA are considered at high risk of recurrent thrombosis and should be treated with VKA in regards of recent randomized controlled trials (RCT) \u003csup\u003e5\u0026ndash;7\u003c/sup\u003e with or without antiplatelet therapy (APT) depending of the underlying comorbidities. Although VKA are the standard of care for patients with TAPS, their daily use is complex due to a narrow therapeutic range requiring regular monitoring of the international normalized ratio (INR) and interactions with drugs and diet. Thus, in clinical practice, patients are often treated with direct oral anticoagulants (DOACs) because of difficulties to obtain a stable INR, bleeding or VKA intolerance. In addition, in case of a first venous thrombotic event and non-high risk APL profile, it is still unclear whether DOACs are an option for anticoagulation \u003csup\u003e8,9\u003c/sup\u003e. There is still need for a better characterization of TAPS patient profiles to identify those who could benefit from DOACs in this indication \u003csup\u003e10,11\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eIn this study, we aimed to report a cohort of patients with TAPS in order to identify risk factors associated with recurrent thrombosis. We also aimed to identify differences between patients treated with VKA and patients treated with DOACs based on real life data.\u003c/p\u003e"},{"header":"2. Methods","content":"\u003cp\u003e2.1 Patients\u003c/p\u003e\n\u003cp\u003eWe conducted a retrospective longitudinal monocentric study in a French referral center. Using a Ehop screening software \u003csup\u003e12\u003c/sup\u003e, we identified patients with persistent positive APL using the following keywords : antiphospholipid syndrome, lupus anticoagulant, anticardiolipin antibodies, anti-\u0026beta;2-glycoprotein-I antibodies. All patients fulfilling the international Sydney criteria \u003csup\u003e1\u003c/sup\u003e for TAPS were included : at least one thrombotic event (involving artery of any caliber, deep vein or microvascular vessels) and persistence of significantly high APL titles at least 12 weeks apart (positive result of LA and/or aCL IgG or IgM and/or a\u0026beta;2GPI IgG or IgM \u0026gt; 99th percentile as per our reference laboratory). Patients were included at TAPS diagnosis defined as the time of the confirmation of persistent APL biology. Long-term antithrombotic treatment was defined as the treatment initiated and/or maintained after diagnosis confirmation.\u003c/p\u003e\n\u003cp\u003eThe following characteristics were collected at APS diagnosis (ie, time of the second APL positivity) :\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAge, gender\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eVenous morbidity defined as any history of previous venous thromboembolism (VTE) event, deep or superficial\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eArterial morbidity defined as any history of atrial fibrillation, peripheral artery disease, arterial embolism, myocardial infarction or ischemic stroke\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiovascular risk factors (smoking, diabetes mellitus, arterial hypertension, dyslipidemia, obesity defined as BMI \u0026gt; 30kg/m\u0026sup2;, oral contraceptive use)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eSystemic auto-immune diseases associated defined as presence of SLE, Sj\u0026ouml;gren syndrome, rheumatoid arthritis, spondyloarthritis or thyroiditis\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eOngoing and previous treatment with APT, VKA, DOACs, statins, hydroxychloroquine and corticosteroids\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003ePreviously known OAPS\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCharacteristics of the primary thrombotic event defined as the thrombotic event leading to TAPS diagnosis. Unusual thrombotic venous localization such as splanchnic vein thrombosis, adrenal vein thrombosis, renal vein thrombosis, cerebral venous thrombosis, pelvic vein thrombosis, upper limb thrombosis were referred as \u0026ldquo;other\u0026rdquo;. Unusual thrombotic arterial localization such as splanchnic arterial thrombosis, adrenal arterial thrombosis, arterial limb thrombosis, renal arterial thrombosis and pelvic arterial thrombosis were referred as \u0026ldquo;other\u0026rdquo;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAPL profile. Single APL positivity was defined as one persistent positivity of LA or aCL or a\u0026beta;2GPI, double APL positivity as two persistent positivity of LA, aCL or a\u0026beta;2GPI, and triple APL positivity as persistent positivity of LA, aCL and a\u0026beta;2GPI.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eDuring follow-up, we also collected the following events: recurrent thrombosis, bleedings and subsequent antithrombotic treatment modifications. Recurrent thrombosis were defined as new vascular occlusion concerning deep vein, artery of any caliber or microvascular vessels confirmed by imaging or histology. Bleedings were reported as major and non-major according to the International Society on Thrombosis and Haemostasis (ISTH) guidelines\u003csup\u003e13\u003c/sup\u003e. Major bleedings were defined as fatal, involving a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, or intramuscular with compartment syndrome, causing a fall in hemoglobin level of 20g/L or more or leading to transfusion of two or more unit of whole blood or red cells. Non-major bleedings were defined as any sign or symptom of hemorrhage requiring medical intervention by a healthcare professional, leading to hospitalization or prompting a face to face evaluation \u003csup\u003e13\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eThe study was approved by a local ethics committee (approval 21.58). All patients were informed by mail of the use of their data and had a 3 weeks deadline after reception to express their opposition to the study.\u003c/p\u003e\n\u003cp\u003e2.2 Statistical analysis\u003c/p\u003e\n\u003cp\u003eContinuous variables were reported as medians (interquartile range (IQR)) or means (standard deviation (SD)) and dichotomous variables by frequency distribution and percentage.\u003c/p\u003e\n\u003cp\u003eRisk factors for recurrent thrombosis and bleedings were identified using a Cox model with competitive risk. Variables with a p-value \u0026lt; 0,2 were included in a multivariate analysis which was followed by a backward stepwise elimination. Colinear variables were not included together in a same model. A two tailed p-value \u0026lt; 0,05 was considered statistically significant. Cumulative incidence curves were also presented using a Cox model.\u003c/p\u003e\n\u003cp\u003eCategorial variables associated with DOACs, VKA, APT alone and no treatment, were identified using logistic regression. Variables with a p-value \u0026lt; 0,2 were included in a multivariate analysis and a backward stepwise elimination was used. Colinear variables were not included together in the same model. A two tailed p-value \u0026lt; 0,05 was considered statistically significant.\u003c/p\u003e\n\u003cp\u003eDirect comparison between treatment groups were performed with chi-square test or Fischer\u0026rsquo;s exact test, when appropriate, for categorical variables and a Student or Mann-Whitney Wilcoxon tests for continuous variables when appropriate.\u003c/p\u003e\n\u003cp\u003eMortality risk comparison used a logrank test.\u003c/p\u003e\n\u003cp\u003eAll statistical analyses were performed using SAS software, version 9.4.\u003c/p\u003e"},{"header":"3. Results","content":"\u003cp\u003e3.1 Patients\u0026rsquo; characteristics\u003c/p\u003e\n\u003cp\u003eOut of 655 patients identified in our department between 2010 and 2021, 246 met Sidney\u0026rsquo;s criteria for APS. Two hundred and seven patients had a TAPS and were included in the analysis (Figure 1).\u003c/p\u003e\n\u003cp\u003eCharacteristics at diagnosis and during follow-up of the 207 patients with TAPS are summarized in Table 1. The mean age at diagnostic was 53.3 years and 45.9% were male. APS was primary in 161 (77.8%) patients and SLE was present at diagnosis in 14 (6.8%) patients. There were 146 (70.5%) venous thromboembolic primary events and 68 (32.9%) arterial primary events. The APL positivity was single in 133 (64.3%) patients, double in 47 (22.7%) patients and triple in 27 (13%) patients. Twenty-seven (13%) patients were treated with APT only after diagnosis confirmation, 123 (59.4%) with VKA, and 45 (24.2%) with DOACs. Seven (3.4%) patients did not benefit of any antithrombotic drug. Mean follow-up was 5.2 years and median follow-up 3.5 years (Table 1).\u003c/p\u003e\n\u003cp\u003eDuring follow-up, 28 (13.5%) recurrent thrombosis occurred (Table 1). Among them, 16 (57.1%) occurred to patients who were treated with VKA, 2 (7.2%) to patients treated with DOACs, 7 (25%) to patients treated with APT only and 3 (10.7%) to patients who had no antithrombotic treatment. Patients with VKA had 7 (43.8%) arterial recurrent thrombosis and 9 (56.3%) recurrent VTE. Patients with DOACs had 2 (100%) recurrent VTE. Patients treated with APT only or without antithrombotic treatment (n = 34) had 6 (60%) recurrent arterial thrombosis and 4 (40%) VTE events. The mean time from diagnosis to recurrence was 3.5 years and median time was 2 years. Death occurred in 12 (5.8%) patients, 7 (3.3%) under VKA, 4 (1.9%) under DOACs, 1 (0.5%) under APT only and none without treatment. Two patients died from hemorrhagic complications (both were in the VKA group) and none from recurrent thrombosis.\u003c/p\u003e\n\u003cp\u003e3.2 Risk factors for thrombotic recurrence\u003c/p\u003e\n\u003cp\u003eRisk factors for recurrent thrombosis in multivariate analysis were SLE (HR = 4.27 [1.31 ; 13.92], p = 0.0160), diabetes mellitus (HR = 10.12 [3.37 ; 30.34], p \u0026lt; 0.0001), anticoagulation before the primary thrombotic event (HR = 3.70 [1.29 ; 10.61], p = 0.0147), previously known OAPS (HR = 7.70 [2.70 ; 21.96], p = 0.0001), no treatment after the primary thrombotic event (HR = 3.43 [1.06 ; 11.08], p = 0.0399) and APT alone after the primary thrombotic event (HR = 4.17 [1.53 ; 11.36], p = 0.0052). DOACs and VKA were not associated with recurrent thrombosis (Table 2).\u003c/p\u003e\n\u003cp\u003eIn the survival analysis, recurrent thrombosis were significantly higher in the group without antithrombotic treatment in comparison with those treated with DOACs (HR = 7.65 [1.18 ; 49.60]) (Figure 2). Recurrent thrombosis tended to be higher in the group without antithrombotic treatment as compared to those treated with VKA (HR = 3.88 [0.99 ; 15.27]) (Figure 2).\u003c/p\u003e\n\u003cp\u003eNo difference in the mortality rates were identified between the four treatment groups (Figure 3).\u003c/p\u003e\n\u003cp\u003e3.3 Clinical and biological characteristics according to initial antithrombotic drugs\u003c/p\u003e\n\u003cp\u003eClinical and biological characteristics according to initial oral anticoagulation (VKA versus DOACs (+/- APT)) are provided in Table 3. Patients with VKA were significantly younger and had more arterial thrombosis, LA positivity and triple APL positivity than those treated with DOACs (Table 3). Conversely, patients with DOACs were significantly older and had more venous thrombosis and single APL positivity.\u003c/p\u003e\n\u003cp\u003eFactors associated with VKA versus DOACs prescription were the presence of LA (OR = 6.97 [1.42 ; 34.10], p \u0026lt; 0.0001), aCL positivity (OR = 3.23 [1.11 ; 9.38], p = 0.0314), a\u0026beta;2GP1 IgM positivity (OR = 3.59 [1.25 ; 10.31], p = 0.0173), triple APL positivity (OR = 7.90 [1.35 ; 46.21], p = 0.0218) and the absence of primary venous thrombosis (OR = 0.01 [0.00 ; 0.25], p = 0.0036) (Table 4).\u003c/p\u003e\n\u003cp\u003e3.4 Bleedings\u003c/p\u003e\n\u003cp\u003eTwenty-seven (13%) bleedings occurred during follow-up. Twenty-two (81.4%) patients were treated with VKA, 3 (11.1%) were treated with DOACs and 2 (7.5%) with APT only. Significantly more bleedings were found in VKA group as compared to DOACs (Table 3).\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eThis monocentric longitudinal study based on real life data confirmed that APS is a high prothrombotic state that should be treated with long term anticoagulation considering the high recurrent thrombosis rate (30%) among patients without oral anticoagulation after initial thrombotic event. APT only and absence of antithrombotic drug after the primary thrombotic event were risk factors associated with recurrent thrombosis.\u003c/p\u003e\n\u003cp\u003eVKA and DOACs were prescribed to 60% and 25% of TAPS patients respectively in our study whereas DOACs prescription is not recommended since RCT showed a higher recurrent thrombosis rate with DOACs (rivaroxaban or apixaban) versus VKA (warfarin). Pengo et al. found an increased risk for recurrent thrombosis in 120 TAPS patients with triple APL positivity when treated with rivaroxaban 20mg daily which ended the study prematurely \u003csup\u003e5\u003c/sup\u003e. Ordi-Ros et al. in their non-inferiority trial comparing warfarin to rivaroxaban 20mg daily in 190 TAPS patients also found a higher thrombotic recurrence risk for patients treated with rivaroxaban especially in the subgroup of patients with primary arterial thrombotic event. Their study included more than 60% of patients with triple APL positivity \u003csup\u003e6\u003c/sup\u003e. Two protocol changes were applied in Woller\u0026rsquo;s trial evaluating efficacy and safety of apixaban in 48 TAPS patients due to the high number of recurrent thrombosis in the apixaban group. Apixaban dosage was increased from 2.5mg twice daily to 5mg twice daily and patients with primary arterial thrombotic event were excluded. In this study which ended prematurely, 30% of patients were triple APL positive \u003csup\u003e7\u003c/sup\u003e. Considering these results, in 2019 the European society of cardiology (ESC) contraindicated the use of DOACs in APS regardless of the type of primary thrombosis and of the serologic profile \u003csup\u003e14\u003c/sup\u003e. Those recommendations were supported in 2020 by the American society of hematology (ASH) and the National Institute for Health and Care Excellence (NICE). Thereafter, a recent meta-analysis of 4 RCTs comparing DOACs to VKA including 474 TAPS patients, with 56.5% of triple-positive APS, did not find increased risk for VTE recurrence when treated with DOACs but confirmed the high recurrence rate of arterial thrombosis, especially stroke, regardless of history of arterial thrombosis and APL profile \u003csup\u003e17\u003c/sup\u003e. In our cohort, only 13% of patients were triple APL positive with 30% of missing data for LA detection. \u003c/p\u003e\n\u003cp\u003eInterestingly, despite a shorter follow-up in DOACs group in comparison with VKA group, DOACs were not associated with recurrent thrombosis in the survival analysis in our study (Table 3). Neither the initial site of thrombosis (primary arterial thrombotic event) nor the APL profile (LA positivity or triple APL positivity) were predictive factors for recurrent thrombosis. Clinical and biological phenotype of TAPS patients treated by DOACs in our study seemed differ from previously cited studies \u003csup\u003e5\u0026ndash;7\u003c/sup\u003e. DOACs were only prescribed to patients with venous primary thrombotic event (only one patient had both splenic artery and splenic vein thrombosis and had no recurrence with DOACs). Eighty percents (80%) of patients treated with DOACs had a single APL positivity and only 2% had triple APL positivity. DOACs prescription according to this APS profile was consistent with previous studies. A single arm prospective study published by Legault et al. followed 82 TAPS patients (none with triple APL positivity) with history of VTE treated with rivaroxaban 20mg daily during a mean follow-up of 19 months and found 4 (5%) recurrent thrombosis, 2 VTE and 2 arterial events with 3 of them being positive for LA. This recurrence rate was within the rates of recurrence of previous RCTs on warfarin use in TAPS \u003csup\u003e9\u003c/sup\u003e. Cohen et al. in their RCT which included solely TAPS with primary VTE event, compared 54 patients treated with rivaroxaban 20mg daily to 56 patients treated with warfarin and did not find any recurrent thrombosis in both groups after 6.5 months of follow-up. The triple APL positivity rate was of 28% in this study \u003csup\u003e8\u003c/sup\u003e. In the post-hoc analysis of TAPS patients in REMEDY I, REMEDY II and RECOVER trials, Goldhaber et al. compared 71 patients treated with dabigatran to 80 patients treated with VKA and did not find differences in the recurrence of VTE with 4.2% in the dabigatran group and 5% in the VKA group \u003csup\u003e18\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eTwo (4%) recurrent thrombosis occurred in the DOACs group during follow-up in our study. This recurrent thrombosis rate seemed to be close to those found in the literature. Doyle et al. retrospectively analyzed 82 TAPS patients with primary VTE event treated with DOACs and found 4 (5%) recurrent thrombosis (2 arterial events and 2 VTE) with a median follow-up of 9 years \u003csup\u003e19\u003c/sup\u003e. Liu et al. retrospectively compared 143 TAPS patients with prior arterial or VTE event and with single APL positivity treated with VKA or DOACs and found no difference in the recurrence rate (6/91 (6.5%) patients in the VKA group and 3/52 (6%) patients in the DOACs group) with a median follow-up of 4.6 years \u003csup\u003e20\u003c/sup\u003e. Our results are also showing similar recurrent thrombosis rates as Brianna et al. who retrospectively compared 166 single or double APS patients, 54 (32.5%) of them being treated with DOACs to 24 triple APS patients among whom 5 (21%) being treated with DOACs. There were 30 (15.8%) recurrent thrombosis, 6 of them being in the triple APS group. Three recurrent thrombosis occurred in DOACs treated patients and two of them were with triple APS \u003csup\u003e21\u003c/sup\u003e. In our study, 28 recurrent thrombosis occurred, 5 of the being in the triple APS group. Two recurrent thrombosis occurred in DOACs treated patients none of them having triple APS positivity.\u003c/p\u003e\n\u003cp\u003eThus, in 2019, the EULAR suggested the possibility of using DOACs in patients already on DOACs for a primary VTE event in whom a single or double APL positivity was found without the presence of LA \u003csup\u003e4\u003c/sup\u003e. Similarly, the 2020 ISTH guidelines, the 2020 BSH (British Society of Hematology) guidelines and the 2020 recommendations of the 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends contraindicated the use of DOACs in patients with APS and arterial thrombosis or triple APL positivity, taking into consideration their use in patients with primary VTE event and single or double APL positivity \u003csup\u003e10,11,22\u003c/sup\u003e. Our results based on real life data confirmed the safety and efficiency of this treatment strategy. All patients with TAPS treated with DOACs should also be reported to the ISTH supported registry (ClinicalTrials.gov Identifier: NCT04262492) to provide real-life data at a larger scale \u003csup\u003e10\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eAmong cardiovascular risk factors collected, diabetes mellitus was significantly associated to recurrent thrombosis in our study which is concordant with Bazzan et al \u003csup\u003e23\u003c/sup\u003e. Hypertension, dyslipidemia and smoking were also associated with arterial events in the literature \u003csup\u003e24,25\u003c/sup\u003e. Previously known SLE and OAPS were risk factors for recurrent thrombosis in our study. Patients with SLE and APL positivity had a higher risk of first thrombotic occurrence in the literature \u003csup\u003e26,27\u003c/sup\u003e but evidence was lacking regarding secondary APS with SLE and higher recurrent thrombosis risk. In Qi et al. cluster analysis of a prospective cohort of 383 APS and asymptomatic APL carriers (among whom 219 with TAPS), cluster 1 which included 44.2% patients with SLE and 57.2% patients with triple APL positivity showed high thrombotic arterial rate (42.8%) and deep venous thrombosis rate (33.3%). Contrary to our result, women with obstetric morbidity were aggregated in cluster 3 in which the proportions of arterial thrombosis (3.6%) and deep venous thrombosis (16.9%) were the lowest \u003csup\u003e28\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eAs in previous studies evaluating TAPS, bleeding risk was similar between DOACs and VKA groups in our Cox model \u003csup\u003e20,29,30\u003c/sup\u003e while DOACs exhibits a safer profile with a lower incidence of cerebral bleeding in nonvalvular atrial fibrillation \u003csup\u003e31\u003c/sup\u003e and VTE \u003csup\u003e32\u003c/sup\u003e . A lack of statistical power for this safety endpoint may explain this result in TAPS studies as the recent meta-analysis by Khairani et al. did not show any difference between DOACs and VKA\u003csup\u003e17\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eWe report real life data on the use of oral anticoagulation for the treatment of TAPS. To our knowledge, this study is the largest retrospective longitudinal cohort evaluating the risks factors of recurrent thrombosis in TAPS and comparing VKA and DOACs, confirming some previously identified risk factors for recurrent thrombosis in TAPS (diabetes mellitus, no antithrombotic treatment or APT only after the primary thrombotic event) and also identifying new ones (SLE, OAPS). The retrospective study is a limitation of this study as some data were missing, including LA detection that could impact a proper APL profile characterization. Another limitation of our work is that we failed in verifying patient adherence to antithrombotic treatments. The INR control at the time of recurrence for VKA treated patients was unknown for most patients. The impact of the new 2023 APS criteria on the way to treat TAPS is yet to be seen\u003csup\u003e33\u003c/sup\u003e.\u003c/p\u003e"},{"header":"5. Conclusion","content":"\u003cp\u003eOur study confirmed some previously identified risk factors for recurrent thrombosis in TAPS and also identified new ones. DOACs were not associated with higher recurrent thrombosis as compared to VKA. Neither the initial site of thrombosis nor the APL profile were predictive of recurrent thrombosis due to oral anticoagulation prescription directed by clinical and biological TAPS profile. In this real-life cohort, DOACs were only prescribed in patients with single or double APL positivity and primary VTE event. VKA were prescribed in patients with triple APL positivity or primary arterial event. The place of DOACs in TAPS remains to be clarified by prospective studies, especially after the publication of the new APS criteria presented as oral communication in Philadelphia in November 2022 \u003csup\u003e34\u003c/sup\u003e.\u003c/p\u003e"},{"header":"Abbreviations ","content":"\u003cp\u003eAPS = antiphospholipid syndrome\u003c/p\u003e\n\u003cp\u003eAPL = antiphospholipid antibodies\u003c/p\u003e\n\u003cp\u003eTAPS = thrombotic antiphospholipid syndrome\u003c/p\u003e\n\u003cp\u003eOAPS = obstetrical antiphospholipid syndrome\u003c/p\u003e\n\u003cp\u003eSLE = systemic lupus erythematosus\u003c/p\u003e\n\u003cp\u003eVTE = venous thromboembolism\u003c/p\u003e\n\u003cp\u003eRCT = randomized controlled trial\u003c/p\u003e\n\u003cp\u003eDVT = deep vein thrombosis\u003c/p\u003e\n\u003cp\u003eAPT = antiplatelet therapy\u003c/p\u003e\n\u003cp\u003eDOACs = direct oral anticoagulants\u003c/p\u003e\n\u003cp\u003eVKA = vitamin K antagonist\u003c/p\u003e\n\u003cp\u003eLA = lupus anticoagulant\u003c/p\u003e\n\u003cp\u003eaCL = anticardiolipin antibodies\u003c/p\u003e\n\u003cp\u003ea\u0026beta;2GPI = anti-\u0026beta;2-glycoprotein-I antibodies\u003c/p\u003e\n\u003cp\u003eNET = neutrophil extracellular traps\u003c/p\u003e\n\u003cp\u003eINR = international normalized ratio\u003c/p\u003e\n\u003cp\u003eESC = European society of cardiology\u003c/p\u003e\n\u003cp\u003eBSH = British Society of Hematology\u003c/p\u003e\n\u003cp\u003eISTH = International Society on Thrombosis and Haemostasis\u003c/p\u003e\n\u003cp\u003eASH =American Society of Hematology\u003c/p\u003e\n\u003cp\u003eNICE = National Institute for Health and Care Excellence\u003c/p\u003e\n\u003cp\u003eNA = not applicable\u003c/p\u003e\n\u003cp\u003eNS = not significant\u003c/p\u003e\n\u003cp\u003eHR = hazard ratio\u003c/p\u003e\n\u003cp\u003eOR = odds ratio\u003c/p\u003e\n\u003cp\u003eSD = standard deviation\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eMiyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). \u003cem\u003eJ Thromb Haemost\u003c/em\u003e. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x\u003c/li\u003e\n\u003cli\u003eKnight JS, Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. \u003cem\u003eSemin Immunopathol\u003c/em\u003e. 2022;44(3):347-362. doi:10.1007/s00281-022-00916-w\u003c/li\u003e\n\u003cli\u003eGarcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. \u003cem\u003eN Engl J Med\u003c/em\u003e. 2018;378(21):2010-2021. doi:10.1056/NEJMra1705454\u003c/li\u003e\n\u003cli\u003eTektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. \u003cem\u003eAnn Rheum Dis\u003c/em\u003e. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213\u003c/li\u003e\n\u003cli\u003ePengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. \u003cem\u003eBlood\u003c/em\u003e. 2018;132(13):1365-1371. doi:10.1182/blood-2018-04-848333\u003c/li\u003e\n\u003cli\u003eOrdi-Ros J, S\u0026aacute;ez-Comet L, P\u0026eacute;rez-Conesa M, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. \u003cem\u003eAnn Intern Med\u003c/em\u003e. 2019;171(10):685-694. doi:10.7326/M19-0291\u003c/li\u003e\n\u003cli\u003eWoller SC, Stevens SM, Kaplan D, et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. \u003cem\u003eBlood Adv\u003c/em\u003e. 2022;6(6):1661-1670. doi:10.1182/bloodadvances.2021005808\u003c/li\u003e\n\u003cli\u003eCohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. \u003cem\u003eLancet Haematol\u003c/em\u003e. 2016;3(9):e426-436. doi:10.1016/S2352-3026(16)30079-5\u003c/li\u003e\n\u003cli\u003eLegault K, Blostein M, Carrier M, et al. A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. \u003cem\u003ePilot Feasibility Stud\u003c/em\u003e. 2020;6(1):52. doi:10.1186/s40814-020-00594-1\u003c/li\u003e\n\u003cli\u003eCohen H, Cuadrado MJ, Erkan D, et al. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. \u003cem\u003eLupus\u003c/em\u003e. 2020;29(12):1571-1593. doi:10.1177/0961203320950461\u003c/li\u003e\n\u003cli\u003eZuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. \u003cem\u003eJ Thromb Haemost\u003c/em\u003e. 2020;18(9):2126-2137. doi:10.1111/jth.14935\u003c/li\u003e\n\u003cli\u003eBouzill\u0026eacute; G, Sylvestre E, Campillo-Gimenez B, et al. An Integrated Workflow For Secondary Use of Patient Data for Clinical Research. \u003cem\u003eStud Health Technol Inform\u003c/em\u003e. 2015;216:913.\u003c/li\u003e\n\u003cli\u003eKaatz S, Ahmad D, Spyropoulos AC, Schulman S, Anticoagulation the S on C of. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. \u003cem\u003eJ Thromb Haemost\u003c/em\u003e. 2015;13(11):2119-2126. doi:10.1111/jth.13140\u003c/li\u003e\n\u003cli\u003eKonstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). \u003cem\u003eEur Heart J\u003c/em\u003e. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405\u003c/li\u003e\n\u003cli\u003eMcCormack T, Harrisingh MC, Horner D, Bewley S. Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing. \u003cem\u003eBMJ\u003c/em\u003e. 2020;369:m1565. doi:10.1136/bmj.m1565\u003c/li\u003e\n\u003cli\u003eOrtel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. \u003cem\u003eBlood Adv\u003c/em\u003e. 2020;4(19):4693-4738. doi:10.1182/bloodadvances.2020001830\u003c/li\u003e\n\u003cli\u003eKhairani CD, Bejjani A, Piazza G, et al. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. \u003cem\u003eJ Am Coll Cardiol\u003c/em\u003e. 2023;81(1):16-30. doi:10.1016/j.jacc.2022.10.008\u003c/li\u003e\n\u003cli\u003eGoldhaber SZ, Eriksson H, Kakkar A, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER\u0026reg;, RE-COVER\u003csup\u003eTM\u003c/sup\u003e II, and RE-MEDY\u003csup\u003eTM\u003c/sup\u003e. \u003cem\u003eVasc Med\u003c/em\u003e. 2016;21(6):506-514. doi:10.1177/1358863X16668588\u003c/li\u003e\n\u003cli\u003eDoyle AJ, Hunt BJ, Danaee A, et al. Direct oral anticoagulant use in patients with antiphospholipid syndrome and unprovoked venous thromboembolism: a single centre experience. \u003cem\u003eBr J Haematol\u003c/em\u003e. 2021;195(2):276-278. doi:10.1111/bjh.17634\u003c/li\u003e\n\u003cli\u003eLiu A, Rupani KV, Naymagon L. Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome. \u003cem\u003eEur J Haematol\u003c/em\u003e. 2022;109(1):69-74. doi:10.1111/ejh.13770\u003c/li\u003e\n\u003cli\u003eBakow BR, Phung Q, Rabinovich D, Olszewski AJ, Reagan JL. Choice of anticoagulation in patients with low risk antiphospholipid syndrome. \u003cem\u003eJ Thromb Thrombolysis\u003c/em\u003e. Published online May 23, 2023. doi:10.1007/s11239-023-02826-6\u003c/li\u003e\n\u003cli\u003eArachchillage DRJ, Gomez K, Alikhan R, et al. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47\u0026ndash;58): use of direct acting oral anticoagulants. \u003cem\u003eBr J Haematol\u003c/em\u003e. 2020;189(2):212-215. doi:10.1111/bjh.16308\u003c/li\u003e\n\u003cli\u003eBazzan M, Vaccarino A, Stella S, et al. Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study). \u003cem\u003eLupus\u003c/em\u003e. 2016;25(5):479-485. doi:10.1177/0961203315617538\u003c/li\u003e\n\u003cli\u003eTaraborelli M, Reggia R, Dall\u0026rsquo;Ara F, et al. Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. \u003cem\u003eJ Rheumatol\u003c/em\u003e. 2017;44(8):1165-1172. doi:10.3899/jrheum.161364\u003c/li\u003e\n\u003cli\u003eNiznik S, Rapoport MJ, Avnery O, et al. Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up. \u003cem\u003eFront Immunol\u003c/em\u003e. 2022;13:843718. doi:10.3389/fimmu.2022.843718\u003c/li\u003e\n\u003cli\u003eTektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. \u003cem\u003eArthritis Rheum\u003c/em\u003e. 2009;61(1):29-36. doi:10.1002/art.24232\u003c/li\u003e\n\u003cli\u003eFarina N, Abdulsalam R, McDonnell T, et al. Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events. \u003cem\u003eRheumatology\u003c/em\u003e. Published online October 13, 2022:keac596. doi:10.1093/rheumatology/keac596\u003c/li\u003e\n\u003cli\u003eQi W, Zhao J, Huang C, et al. Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study. \u003cem\u003eArthritis Res Ther\u003c/em\u003e. 2022;24(1):140. doi:10.1186/s13075-022-02814-w\u003c/li\u003e\n\u003cli\u003eWilliams B, Saseen JJ, Trujillo T, Palkimas S. Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome. \u003cem\u003eJ Thromb Thrombolysis\u003c/em\u003e. 2022;54(1):67-73. doi:10.1007/s11239-021-02587-0\u003c/li\u003e\n\u003cli\u003eMalec K, Broniatowska E, Undas A. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. \u003cem\u003eLupus\u003c/em\u003e. 2020;29(1):37-44. doi:10.1177/0961203319889156\u003c/li\u003e\n\u003cli\u003ePatel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. \u003cem\u003eN Engl J Med\u003c/em\u003e. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638\u003c/li\u003e\n\u003cli\u003eEINSTEIN\u0026ndash;PE Investigators, B\u0026uuml;ller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. \u003cem\u003eN Engl J Med\u003c/em\u003e. 2012;366(14):1287-1297. doi:10.1056/NEJMoa1113572\u003c/li\u003e\n\u003cli\u003eBarbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. \u003cem\u003eArthritis Rheumatol\u003c/em\u003e. 2023;n/a(n/a). doi:10.1002/art.42624\u003c/li\u003e\n\u003cli\u003eBarbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. \u003cem\u003eArthritis Care Res\u003c/em\u003e. 2021;73(10):1490-1501. doi:10.1002/acr.24520\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cu\u003eTable 1 : Characteristics at diagnosis and during follow-up in 207 patients with TAPS fulfilling international Sydney criteria\u003c/u\u003e\u003c/p\u003e\n\u003ctable border=\"1\" width=\"93%\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eParameters\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOverall population\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eN = 207\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePatients with thrombotic recurrence\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eN= 28\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePatients without thrombotic recurrence\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eN = 179\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"NaN%\"\u003e\n\u003cp\u003e\u003cstrong\u003eClinical characteristics and comorbidities at diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAge, years,\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003emean \u0026plusmn; SD (median)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e53.3 \u0026plusmn; 17.7 (54.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e48.0 \u0026plusmn; 18 (48.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e54.2 \u0026plusmn; 17.5 (55.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMale gender\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e95 (45.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e4 (14.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e91 (50.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHistory of tobacco use\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e93 (45.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e15 (53.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e78 (43.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHypertension\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e59 (28.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e9 (32.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e50 (27.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDiabetes mellitus\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e7 (3.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e4 (14.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e3 (1.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDyslipidemia\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e42 (20.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e7 (25.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e35 (19.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eObesity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e24 (11.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e4 (14.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e20 (11.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAutoimmune disease\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e46 (22.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e10 (35.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e36 (20.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSLE\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e14 (6.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e5 (17.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e9 (5.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eArterial morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e36 (17.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e2 ( 7.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e34 (19.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVenous morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e49 (23.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e46 (25.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePregnancy morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e23 (11.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e9 (32.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e14 (7.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePreviously known OAPS\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e6 (2.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e4(14.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e2 (1.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"NaN%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePrimary thrombotic event *\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eArterial thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e68 (32.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e11 (39.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e57 (31.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eIschemic stroke\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e46 (22.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e6 (21.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e40 (22.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMyocardial infarction\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e6 (2.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e1 ( 3.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e5 (2.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOther\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e17 (8.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e14 (7.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVenous thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e146 (68.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e19 (67.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e127 (70.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eProximal deep vein thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e74 (35.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e11 (39.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e63 (35.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePulmonary embolism\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e91 (44.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e12 (42.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e79 (44.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOther\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e18 (8.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e0 (0.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e18 (10.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"NaN%\"\u003e\n\u003cp\u003e\u003cstrong\u003eBiological characteristics at diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eLA detected\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e56 (27.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e8 (28.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e48 (26.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e113 (54.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e21 (75.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e92 (51.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL IgG positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e73 (36.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e13 (54.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e60 (34.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL IgM positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e50 (25.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e7 (30.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e43 (25.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1 positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e137 (66.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e17 (60.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e120 (67.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1 IgG positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e78 (41.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e8 (40.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e70 (41.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;IgM positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e68 (37.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e6 (30.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e62 (37.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSingle positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e133 (64.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e15 (53.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e118 (65.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDouble positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e47 (22.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e8 (28.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e39 (21.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eTriple positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e27 (13.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e5 (17.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e22 (12.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"NaN%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMedications before diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAPT\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e32 (15.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e29 (16.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAnticoagulant drugs\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e7 (3.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e4 (2.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eStatin\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e27 (13.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e1 (3.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e26 (14.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHydroxychloroquine\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e5 (2.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e2 (7.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e3 (1.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVitamin D\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e9 (4.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e2 (7.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e7 (3.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAntihypertensive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e60 (29.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e9 (32.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e51 (28.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOral estroprogestative contraception\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e16 (7.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e1 (3.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e15 (8.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOral progestative contraception\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e3 (1.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e0 (0.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e3 (1.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"NaN%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAntithrombotic drugs after the primary thrombotic event\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eNo antithrombotic drug\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e7 (3.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e4(2.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAPT only\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e27 (13.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e7 (25.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e20 (11.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVKA +/- APT\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e123 (59.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e16 (57.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e107 (59.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDOACs +/- APT\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e50 (24.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e2 (7.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e48 (26.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"NaN%\"\u003e\n\u003cp\u003e\u003cstrong\u003eFollow-up\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eFollow-up,\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003eyears, mean \u0026plusmn; SD (median)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e5.2 \u0026plusmn; 4.9 (3.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e10.0 \u0026plusmn; 6.6 (10)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e4.4 \u0026plusmn; 4.1 (3.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eTime to recurrence, years, mean \u0026plusmn; SD (median)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e3.5 \u0026plusmn; 3.5 (2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"41.83673469387755%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDeath\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.3265306122449%\"\u003e\n\u003cp\u003e12 (5.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"21.428571428571427%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.408163265306122%\"\u003e\n\u003cp\u003e9 (5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e* Patients may have experienced more than one thrombotic event leading to TAPS diagnosis. TAPS = thrombotic antiphospholipid syndrome ; OAPS = obstetrical antiphospholipid syndrome ; SLE \u0026nbsp;= systemic lupus erythematosus ; a\u0026beta;2GP1 = Anti-\u0026beta;-2-glycoprotein-1 ; aCL = Anti-cardiolipin ; LA = Lupus anticoagulant ; APT = antiplatelet therapy ; VKA = vitamin K antagonist ; DOACs = direct oral anticoagulants ; SD = standard deviation ; NA = not applicable\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eTable 2 \u0026nbsp;: \u0026nbsp;Risk factors for recurrent thrombosis in 207 patients with TAPS\u003c/u\u003e\u003c/p\u003e\n\u003ctable border=\"1\" width=\"977\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eParameters\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e\u003cstrong\u003eThrombotic recurrence (n = 28)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e\u003cstrong\u003eNo thrombotic\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003erecurrence (n = 179)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e\u003cstrong\u003eUnivariate HR\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e\u003cstrong\u003e95% CI\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e\u003cstrong\u003eUnivariate\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ep value\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMultivariate HR\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e95% CI\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMultivariate\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ep value\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"9\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eClinical characteristics and comorbidities\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMale gender\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e4 (14.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e91 (50.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.27\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.09 ; 0.77]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.0151\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003eNS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHistory of tobacco use\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e15 (53.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e78 (43.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.21\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.58 ; 2.53]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.6151\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHypertension\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e9 (32.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e50 (27.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.41\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.64 ; 3.09]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.3942\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDiabetes mellitus\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e4 (14.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e3 (1.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e4.74\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[1.68 ; 13.38]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.0033\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e10.12\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e[3.37 ; 30.34]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026lt; 0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDyslipidemia\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e7 (25%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e35 (19.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.41\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.62 ; 3.41]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.3942\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eObesity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e4 (14.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e20 (11.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.35\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.46 ; 3.99]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.5861\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAutoimmune disease\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e10 (35.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e36 (20.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.83\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.84 ; 3.98]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.1259\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026sect;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSLE\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e5 (17.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e9 (5.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e3.56\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[1.23 ; 10.29]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.0190\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e4.27\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e[1.31 ; 13.92]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e0.0160\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eArterial morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e2 (7.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e34 (19.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.41\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.10 ; 1.68]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.2130\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVenous morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e46 (25.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.45\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.14 ; 1.45]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.1784\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003eNS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePregnancy morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e9 (32.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e14 (7.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e2.89\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[1.37 ; 6.14]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.0056\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePreviously known OAPS\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e4 (14.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e2(1.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e4.95\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[1.88 ; 13.00]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.0012\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e7.70\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e[2.70 ; 21.96]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"9\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePrimary thrombotic event*\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eArterial thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e11 (39.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e57 (31.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.00\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.45 ; 2.23]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.9946\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;Ischemic stroke\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e6 (21.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e40 (22.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.75\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.30 ; 1.87]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.5304\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; Myocardial infarction\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e1 (3.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e5 (2.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.57\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.07 ; 5.00]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.6153\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; Other\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e14 (7.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.33\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.36 ; 4.95]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.6660\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVenous thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e19 (67.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e127 (70.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.14\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.50 ; 2.63]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.7547\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; Proximal deep vein thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e11 (39.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e63 (35.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.17\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.56 ; 2.46]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.6821\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; Pulmonary embolism\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e12 (42.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e79 (44.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.16\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.55 ; 2.43]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.6929\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; \u0026nbsp;Other\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e0 (0.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e18 (10.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.22\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.01 ; 3.82]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.3002\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"9\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eBiological characteristics at diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eLA detected\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e8 (28.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e48 (26.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.07\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.36 ; 3.17]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.4401\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e21 (75.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e92 (51.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e2.09\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.89 ; 4.90]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.0906\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003eNS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL IgG positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e13 (54.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e60 (34.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.50\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.66 ; 3.37]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.3302\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL IgM positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e7 (30.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e43 (25.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.58\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.65 ; 3.82]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.3123\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1 positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e17 (60.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e120 (67.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.97\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.45 ; 2.08]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.9327\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1 IgG positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e8 (40.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e70 (41.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.97\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.40 ; 2.33]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.9456\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1 IgM positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e6 (30.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e62 (37.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.66\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.25 ; 1.74]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.4040\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSingle positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e15 (53.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e118 (65.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.69\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.33 ; 1.44]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.3219\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDouble positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e8 (28.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e39 (21.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.26\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.55 ; 2.90]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.5868\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eTriple positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e5 (17.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e22 (12.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.42\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.56 ; 3.59]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.4586\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"9\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMedications before diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAPT\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e29 (16.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.74\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.23 ; 2.41]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.6154\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAnticoagulant drugs\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e4 (2.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e2.59\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[1.02 ; 6.55]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.0449\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e3.70\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e[1.29 ; 10.61]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e0.0147\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eStatin\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e1 (3.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e26 (14.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.29\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.04 ; 2.16]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.2255\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVitamin D\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e2 (7.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e7 (3.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e2.12\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.43 ; 10.42]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.3537\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAntihypertensive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e9 (32.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e51 (28.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.45\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.66 ; 3.20]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.3556\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOral oestroprogestative contraception\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e1 (3.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e15 (8.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.27\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.03 ; 2.12]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.2141\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOral progestative contraception\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e0 (0.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e3 (1.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.48\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.03 ; 8.25]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.6099\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"9\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDrugs after first thrombotic event\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eNo antithrombotic drug\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e4 (2.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e5.14\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[2.17 ; 12.19]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.0002\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e3.43\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e[1.06 ; 11.08]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e0.0399\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAPT only\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e7 (25.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e20 (11.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e2.23\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.94 ; 5.27]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.0685\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e4.17\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e[1.53 ; 11.36]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e0.0052\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVKA +/- APT\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e14 (50.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e107 (59.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.62\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.29 ; 1.32]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.2172\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDOACs +/- APT\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e2 (7.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e48 (26.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.38\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.09 ; 1.59]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.1841\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003eNS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eStatin\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e5 (17.8%)\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e50 (27.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.51\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.19 ; 1.36]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.1765\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003eNS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eD vitamin\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e2 (7.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e16 (8.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e0.85\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.20 ; 3.72]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.8314\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"21.59672466734903%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHydroxychloroquine\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"12.99897645854657%\"\u003e\n\u003cp\u003e3 (10.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.849539406345958%\"\u003e\n\u003cp\u003e11 (6.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"6.448311156601842%\"\u003e\n\u003cp\u003e1.22\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e[0.33 ; 4.48]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.723643807574208%\"\u003e\n\u003cp\u003e0.7629\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.951893551688844%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.597748208802457%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.109518935516888%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eFollowing variables were included in the Cox model for multivariate analysis : Previously known diabetes mellitus, previously known SLE, venous morbidity, previously known OAPS, arterial thrombosis at diagnosis, a\u0026beta;2GP1, aCL, LA, anticoagulant drugs taken before diagnosis, no antithrombotic drug after diagnosis, APT only after diagnosis, VKA +/- APT after diagnosis, DOACs +/-APT after diagnosis and statin after diagnosis. Stepwise elimination was then made. a\u0026beta;2GP1 = Anti-\u0026beta;-2-glycoprotein-1 ; aCL = Anti-cardiolipin ; LA = Lupus anticoagulant ; SLE \u0026nbsp;= systemic lupus erythematosus \u0026nbsp;OAPS = obstetrical antiphospholipid syndrome ; TAPS = thrombotic antiphospholipid ; APT = antiplatelet therapy ; VKA = vitamin K Antagonist ; DOACs = direct anticoagulants ; HR = hazard ratio ; CI = confidence interval ; syndrome ; NS = not significant.\u003c/p\u003e\n\u003cp\u003e* Patients may have experienced more than one thrombotic event leading to TAPS diagnosis. \u0026sect; Colinear variables weren\u0026rsquo;t included together in the same model.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eTable 3. Clinical and biological characteristics according to initial oral anticoagulation (VKA versus DOACs) in 173 TAPS patients\u003c/u\u003e\u003c/p\u003e\n\u003ctable border=\"1\" width=\"604\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eParameters\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVKA+/-APT\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003en= 123\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDOACs +/-APT\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003en= 50\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eClinical characteristics and comorbidities at diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAge, years, mean \u0026plusmn; SD\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(median)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e51.8 \u0026plusmn; 17.5 (53.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e61.1 \u0026plusmn; 16.2 (62.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.0014\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMale gender\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e56 (45.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e22 (44%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.8547\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHistory of tobacco use\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e62 (50.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e15 (30.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.0127\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHypertension\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e38 (30.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e16 (32.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.8869\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDiabetes mellitus\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e6 (4.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e1 (2.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.6747\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDyslipidemia\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e26 (21.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e11 (22.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.9003\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eObesity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e16 (13.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e6 (12.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.8568\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAutoimmune disease\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e32 (26.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e7 (14.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.0864\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSystemic lupus erythematosus associated\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e9 (7.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e2 (4.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.5143\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eArterial morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e24 (19.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e8 (16.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.5897\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVenous morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e28 (22.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e16 (32.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.2061\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePregnancy morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e14 (11.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e2 (4.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.1571\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePrimary thrombotic event *\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eArterial thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e52 (42.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e1 (2.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e\u0026lt; 0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eIschemic stroke\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e37 (30.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e0 (0.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e\u0026lt; 0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMyocardial infarction\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e6 (4.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e0 (0.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.1833\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOther\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e12 (9.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e1 (2.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0,0698\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVenous thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e74 (60.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e50 (100.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e\u0026lt; 0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eProximal DVT\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e34 (27.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e25 (50.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.0049\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePulmonary embolism\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e45 (36.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e37 (74.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e\u0026lt; 0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOther\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e13 (10.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e4 (8.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.7807\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eBiological characteristics at diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eLupus anticoagulant detected\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e42 (34.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e2 (4.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e\u0026lt; 0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL positive\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e69 (56.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e25 (50.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.4655\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL IgG positive\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e50 (43.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e14 (28.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.0800\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL IgM positive\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e29 (25.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e12 (24.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.8981\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003epositive\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e90 (73.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e33 (66.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.3456\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;IgG positive\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e52 (48.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e20 (40.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.3655\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;IgM positive\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e47 (45.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e15 (30.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.0865\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSingle positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e68 (55.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e40 (80.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.0023\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDouble positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e32 (26.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e9 (18.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.2610\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eTriple positivity\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e23 (18.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e1 (2.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.0040\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSecondary events during follow-up\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eFollow-up, years,\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003emean \u0026plusmn; SD\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(median)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e5.5 \u0026plusmn; 4.5 (4.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e2.6 \u0026plusmn; 1.7 (2.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e\u0026lt; 0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eTime to recurrent thrombosis, years, mean \u0026plusmn; SD (median)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e3.6 \u0026plusmn; 3.7 (2.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e1.2 \u0026plusmn; 0.8 (1.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eRecurrent thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e16 (13.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e2 (4.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.0786\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eArterial thrombosis\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e7 (43.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e2 (100.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.4706\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; Ischemic stroke\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e5 (71.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e1 (50.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; Myocardial infarction\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;Other\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e2 (28.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e1 (50.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVenous thrombosis\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e9 (56.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eIsolated proximal\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;DVT\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e1 (11.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;Pulmonary embolism +/-DVT\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e7 (77.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOther\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e1 (11.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003eNA\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eBleedings\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e22 (17.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e3 (6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0,0438\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; Major bleedings\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e17 (13.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e3 (6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0,1447\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;Non major bleedings\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e5 (4.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0,3231\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDeath\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e7 (5.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e4 (8.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.7317\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"44.79338842975206%\"\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment change\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"20.66115702479339%\"\u003e\n\u003cp\u003e37 (30.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"19.00826446280992%\"\u003e\n\u003cp\u003e18 (36.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"15.537190082644628%\"\u003e\n\u003cp\u003e0.4486\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eTAPS = thrombotic antiphospholipid syndrome; APT = antiplatelet therapy ; VKA = vitamin K antagonist ; DOACs = direct oral anticoagulants ; SLE \u0026nbsp;= systemic lupus erythematosus ; DVT = deep vein thrombosis ; a\u0026beta;2GP1 = Anti-\u0026beta;-2-glycoprotein-1 ; aCL = Anti-cardiolipin ; LA = Lupus anticoagulant ; NA = not applicable ; SD = standard deviation. * Patients may have experienced more than one thrombotic event leading to TAPS diagnosis.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eTable 4 : Factors associated with the initial prescription of VKAs versus DOACs in 173 TAPS patients :\u003c/u\u003e\u003c/p\u003e\n\u003ctable border=\"1\" width=\"100%\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eParameters\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVKA +/- APT\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e(n = 123)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDOACs +/- APT\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e(n = 50)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e\u003cstrong\u003eUnivariate OR\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e\u003cstrong\u003e95% CI\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e\u003cstrong\u003eUnivariate\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ep value\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMultivariate OR\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e95% CI\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMultivariate\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ep value\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"9\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eClinical characteristics and comorbidities at diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMale gender\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e56 (45.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e22 (44%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.06\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.55 ; 2.06]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.8547\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHistory of tobacco use\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e62 (50.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e15 (30.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e2.41\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[1.20 ; 4.86]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0139\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003eNS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHypertension\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e38 (30.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e16 (32.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e0.95\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.47 ; 1.93]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.8864\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDiabetes mellitus\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e6 ( 4.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e1 (2.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e2.51\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.29 ; 21.42]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.3994\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDyslipidemia\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e26 (21.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e11 (22.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e0.95\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.43 ; 2.11]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.8997\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eObesity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e16 (13.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e6 (12.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.40 ; 2.99]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.8569\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAutoimmune disease\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e32 (26.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e7 (14.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e2.16\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.88 ; 5.28]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0916\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSLE\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e9 (7.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e2 (4.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.89\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.39 ; 9.10]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.4246\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eArterial morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e24 (19.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e8 (16.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.27\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.53 ; 3.06]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.5903\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVenous morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e28 (22.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e16 (32.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e0.63\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.30 ; 1.30]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.2080\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003ePregnancy morbidity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e14 (11.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e2 (4.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e3.08\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.67 ; 14.09]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.1466\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003eNS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"9\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eInitial clinical event *\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eArterial thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e52 (42.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e1 (2.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e37.08\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[4.96 ; 277.13]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0004\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003eNS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;Ischemic stroke\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e37 (30.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e0 (0.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e43.79\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e\u0026nbsp;[2.54 ; 756.34]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0093\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026sect;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; Myocardial infarction\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e6 ( 4.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e0 (0.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e5.59\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.25 ; 127.45]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.2804\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp; Other\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e12 (9.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e1 (2,0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e4.03\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.68 ; 23.86]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.1244\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026sect;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVenous thrombosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e74 (60.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e50 (100.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e0.01\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.00 ; 0.25]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0037\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e0.01\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e[0.00 ; 0.25]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e0.0036\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eProximal DVT\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e34 (27.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e25 (50.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e0.38\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.19 ; 0.75]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0056\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026sect;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;Pulmonary embolism\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e45 (36.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e37 (74.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e0.20\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.10 ; 0.42]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e\u0026lt;0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026sect;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOther\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e13 (10.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e4 (8.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.36\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.42 ; 4.39]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.6081\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"9\" valign=\"top\" width=\"100%\"\u003e\n\u003cp\u003e\u003cstrong\u003eBiological\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003echaracteristics at diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eLA detected\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e42 (34.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e2 (4.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e7.96\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e\u0026nbsp;[1.64 ; 38.61]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e\u0026lt; 0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e6.97\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e[1.42 ; 34.10]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026lt; 0.0001\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e69 (56.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e25 (50.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.28\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.66 ; 2.47]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.4659\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e3.23\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026nbsp;[1.11 ; 9.38]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e0.0314\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003eIgG positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e50 (43.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e14 (28.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.89\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.92 ; 3.89]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0823\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026sect;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaCL\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;IgM positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e29 (25.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e12 (24.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.05\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.48 ; 2.28]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.8987\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1 positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e90 (73.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e33 (66.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.40\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.69 ; 2.85]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.3466\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1 IgG positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e52 (48.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e20 (40.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.37\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.69 ; 2.72]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.3662\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003ea\u0026beta;2GP1 IgM positive\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e47 (45.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e15 (30.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.87\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.91 ; 3.84]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0887\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e3.59\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e[1.25 ; 10.31]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e0.0173\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSingle positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e68 (55.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e40 (80.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e0.31\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[0.14 ; 0.67]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0031\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003eNS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDouble positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e32 (26.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e9 (18.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e1.60\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e\u0026nbsp;[0.70 ; 3.66]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.2639\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"22.105263157894736%\"\u003e\n\u003cp\u003e\u003cstrong\u003eTriple positivity\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e23 (18.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e1 (2.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.526315789473685%\"\u003e\n\u003cp\u003e11.26\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"9.473684210526315%\"\u003e\n\u003cp\u003e[1.48 ; 85.74]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"7.368421052631579%\"\u003e\n\u003cp\u003e0.0194\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"11.578947368421053%\"\u003e\n\u003cp\u003e7.90\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e[1.35 ; 46.21]\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"8.421052631578947%\"\u003e\n\u003cp\u003e0.0218\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eTwo multivariate analysis were performed. Following variables were included in the first cox model: history of tobacco use, pregnancy morbidity, arterial thrombosis, venous thrombosis, LA detected, aCL, a\u0026beta;2GP1 IgM. Stepwise elimination was then made. Following variables were included in the second cox model: history of tobacco use, pregnancy morbidity, arterial thrombosis, venous thrombosis, single positivity and triple positivity. Stepwise regression was then made. \u0026sect; Colinear variables weren\u0026rsquo;t included together in the same model. TAPS = thrombotic antiphospholipid syndrome ; APT = antiplatelet therapy ; VKA = vitamin K antagonist ; DOACs = direct oral anticoagulants ; SLE = systemic lupus erythematosus ; DVT = deep vein thrombosis ; a\u0026beta;2GP1 = Anti-\u0026beta;-2-glycoprotein-1 ; aCL = Anti-cardiolipin ; LA = Lupus anticoagulant ; OR = odds ratio ; CI = confidence interval ; NS = not significant. * Patients may have experienced more than one thrombotic event leading to TAPS diagnosis.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Centre Hospitalier Universitaire de Rennes","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"thrombosis, antiphospholipid syndrome, vitamin K antagonist, direct oral anticoagulants ","lastPublishedDoi":"10.21203/rs.3.rs-3951851/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3951851/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cem\u003eIntroduction :\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAntiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of autoantibodies (anti-cardiolipin, anti-β2GP1, and lupus anticoagulant) associated with arterial, venous, or microcirculatory thrombotic events and/or obstetrical events (miscarriages, fetal death, and preterm deliveries). The treatment of thrombotic events is based on long-term anticoagulant therapy with vitamin K antagonist (VKA). Direct oral anticoagulants (DOACs) are not recommended by international guidelines as first-line therapy because of an increased risk of recurrent thrombosis observed in several randomized trials. This study aimed to report a cohort of patients with thrombotic antiphospholipid syndrome (TAPS) to identify risk factors associated with recurrent thrombosis and to identify differences between patients treated with VKA and patients treated with DOACs.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eMaterials and methods :\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eWe collected data from 207 patients with TAPS from an initial population of 655 patients identified by automated screening software.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eResults :\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThis retrospective longitudinal analysis based on real-life data confirmed previously identified risk factors for thrombotic recurrence, such as the absence of antithrombotic treatment following the initial thrombotic event, treatment with antiplatelet treatment alone following the initial thrombotic event. No difference between patients treated with VKA (n=123) or DOACs (n=50) were observed on the risk of recurrent thrombosis. Patients with VKA versus DOACs had more frequently triple APL positivity, presence of lupus anticoagulant and absence of an initial venous thrombotic event.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eConclusions :\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThis results suggest a potential use of DOACs in the treatment of TAPS for patients with a primary VTE event and a single APL positivity profile, although its retrospective design prevents firm recommendations.\u003c/p\u003e","manuscriptTitle":"Risk factors for recurrent thrombosis and comparison of DOACs vs VKA in selected thrombotic antiphospholipid syndrome","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-02-13 18:46:21","doi":"10.21203/rs.3.rs-3951851/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"0953ed1e-b972-4f15-849e-c0b20ff2de1a","owner":[],"postedDate":"February 13th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":28723378,"name":"Internal Medicine"}],"tags":[],"updatedAt":"2024-02-13T18:46:21+00:00","versionOfRecord":[],"versionCreatedAt":"2024-02-13 18:46:21","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3951851","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3951851","identity":"rs-3951851","version":["v1"]},"buildId":"FbvkV6FR0MCFSLy54lSbu","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}